AU2001249315A1 - Ecdysone receptor-based inducible gene expression system - Google Patents
Ecdysone receptor-based inducible gene expression systemInfo
- Publication number
- AU2001249315A1 AU2001249315A1 AU2001249315A AU4931501A AU2001249315A1 AU 2001249315 A1 AU2001249315 A1 AU 2001249315A1 AU 2001249315 A AU2001249315 A AU 2001249315A AU 4931501 A AU4931501 A AU 4931501A AU 2001249315 A1 AU2001249315 A1 AU 2001249315A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- polypeptide
- gene expression
- binding domain
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims description 290
- 108010057988 ecdysone receptor Proteins 0.000 title claims description 287
- 230000001939 inductive effect Effects 0.000 title description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 417
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 415
- 229920001184 polypeptide Polymers 0.000 claims description 413
- 108090000623 proteins and genes Proteins 0.000 claims description 262
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 197
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 197
- 102000040430 polynucleotide Human genes 0.000 claims description 172
- 108091033319 polynucleotide Proteins 0.000 claims description 172
- 239000002157 polynucleotide Substances 0.000 claims description 172
- 150000007523 nucleic acids Chemical group 0.000 claims description 134
- 210000004027 cell Anatomy 0.000 claims description 132
- 230000027455 binding Effects 0.000 claims description 115
- 150000003431 steroids Chemical class 0.000 claims description 82
- 230000004568 DNA-binding Effects 0.000 claims description 81
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 75
- 230000035772 mutation Effects 0.000 claims description 73
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 64
- -1 CH2C1 Chemical compound 0.000 claims description 58
- 108020001756 ligand binding domains Proteins 0.000 claims description 55
- 230000035945 sensitivity Effects 0.000 claims description 55
- 108091027981 Response element Proteins 0.000 claims description 51
- 239000003446 ligand Substances 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 102000006255 nuclear receptors Human genes 0.000 claims description 31
- 108020004017 nuclear receptors Proteins 0.000 claims description 31
- 102000005962 receptors Human genes 0.000 claims description 30
- 108020003175 receptors Proteins 0.000 claims description 30
- 102100039556 Galectin-4 Human genes 0.000 claims description 29
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 26
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 26
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- 238000006471 dimerization reaction Methods 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 12
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 12
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 12
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 12
- 229920002554 vinyl polymer Polymers 0.000 claims description 12
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 9
- 239000000833 heterodimer Substances 0.000 claims description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 8
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 6
- 210000005253 yeast cell Anatomy 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 241000282577 Pan troglodytes Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 4
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000006530 (C4-C6) alkyl group Chemical group 0.000 claims 3
- 125000006532 (C3-C5) alkyl group Chemical group 0.000 claims 2
- 238000012217 deletion Methods 0.000 description 95
- 230000037430 deletion Effects 0.000 description 95
- 108020004414 DNA Proteins 0.000 description 90
- 102000004169 proteins and genes Human genes 0.000 description 85
- 235000018102 proteins Nutrition 0.000 description 84
- 102000039446 nucleic acids Human genes 0.000 description 66
- 108020004707 nucleic acids Proteins 0.000 description 66
- 239000002773 nucleotide Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- 125000003729 nucleotide group Chemical group 0.000 description 33
- 230000001105 regulatory effect Effects 0.000 description 32
- 239000013598 vector Substances 0.000 description 32
- 108091026890 Coding region Proteins 0.000 description 25
- 241000196324 Embryophyta Species 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 24
- 238000013518 transcription Methods 0.000 description 24
- 230000035897 transcription Effects 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 22
- 241000238631 Hexapoda Species 0.000 description 20
- 108700008625 Reporter Genes Proteins 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 238000001890 transfection Methods 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 102000053602 DNA Human genes 0.000 description 14
- 101100279027 Drosophila melanogaster EcR gene Proteins 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- 230000004913 activation Effects 0.000 description 13
- 239000003623 enhancer Substances 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 230000036961 partial effect Effects 0.000 description 13
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 12
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 108060001084 Luciferase Proteins 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 230000008488 polyadenylation Effects 0.000 description 11
- 230000003637 steroidlike Effects 0.000 description 11
- 241000255942 Choristoneura fumiferana Species 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000003270 steroid hormone Substances 0.000 description 8
- 102000005969 steroid hormone receptors Human genes 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000005495 thyroid hormone Substances 0.000 description 7
- 229940036555 thyroid hormone Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- LQGNCUXDDPRDJH-UHFFFAOYSA-N 3'-GMP Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21 LQGNCUXDDPRDJH-UHFFFAOYSA-N 0.000 description 6
- 108091033380 Coding strand Proteins 0.000 description 6
- LRJUYAVTHIEHAI-UHFFFAOYSA-N Muristeron A Natural products C1C(O)C(O)CC2(C)C(C(O)CC3(C(C(C)(O)C(O)CCC(C)C)CCC33O)C)C3=CC(=O)C21O LRJUYAVTHIEHAI-UHFFFAOYSA-N 0.000 description 6
- LRJUYAVTHIEHAI-LHBNDURVSA-N Muristerone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O LRJUYAVTHIEHAI-LHBNDURVSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- QYYXITIZXRMPSZ-UHFFFAOYSA-N n'-tert-butyl-n'-(3,5-dimethylbenzoyl)-2-ethyl-3-methoxybenzohydrazide Chemical compound CCC1=C(OC)C=CC=C1C(=O)NN(C(C)(C)C)C(=O)C1=CC(C)=CC(C)=C1 QYYXITIZXRMPSZ-UHFFFAOYSA-N 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000010396 two-hybrid screening Methods 0.000 description 6
- PJYYBCXMCWDUAZ-JJJZTNILSA-N 2,3,14,20,22-pentahydroxy-(2β,3β,5β,22R)-Cholest-7-en-6-one Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 PJYYBCXMCWDUAZ-JJJZTNILSA-N 0.000 description 5
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 5
- 241000235648 Pichia Species 0.000 description 5
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 5
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 4
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 4
- 235000009854 Cucurbita moschata Nutrition 0.000 description 4
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 4
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 241000255588 Tephritidae Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 108020003113 steroid hormone receptors Proteins 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 101710096438 DNA-binding protein Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 108010001515 Galectin 4 Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 3
- 108010052090 Renilla Luciferases Proteins 0.000 description 3
- 108010034634 Repressor Proteins Proteins 0.000 description 3
- 102000009661 Repressor Proteins Human genes 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 244000062793 Sorghum vulgare Species 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108010085012 Steroid Receptors Proteins 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000002363 herbicidal effect Effects 0.000 description 3
- 239000004009 herbicide Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- 240000004507 Abelmoschus esculentus Species 0.000 description 2
- 101100279024 Aedes aegypti EcR gene Proteins 0.000 description 2
- 101000967325 Aedes aegypti Ecdysone receptor Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 241000209763 Avena sativa Species 0.000 description 2
- 235000000832 Ayote Nutrition 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 101100279025 Bombyx mori EcR gene Proteins 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- 235000010773 Cajanus indicus Nutrition 0.000 description 2
- 244000105627 Cajanus indicus Species 0.000 description 2
- 241001249699 Capitata Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 235000009467 Carica papaya Nutrition 0.000 description 2
- 240000006432 Carica papaya Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 241000255579 Ceratitis capitata Species 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 235000010523 Cicer arietinum Nutrition 0.000 description 2
- 244000045195 Cicer arietinum Species 0.000 description 2
- 244000241235 Citrullus lanatus Species 0.000 description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- 241000219112 Cucumis Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 240000004244 Cucurbita moschata Species 0.000 description 2
- 240000001980 Cucurbita pepo Species 0.000 description 2
- 235000009852 Cucurbita pepo Nutrition 0.000 description 2
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 101000967334 Heliothis virescens Ecdysone receptor Proteins 0.000 description 2
- 241000258937 Hemiptera Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 description 2
- 244000017020 Ipomoea batatas Species 0.000 description 2
- 241000238114 Leptuca pugilator Species 0.000 description 2
- 241000254022 Locusta migratoria Species 0.000 description 2
- 241000920471 Lucilia caesar Species 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000220225 Malus Species 0.000 description 2
- 101100388642 Manduca sexta EcR gene Proteins 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 241000721621 Myzus persicae Species 0.000 description 2
- 108090001145 Nuclear Receptor Coactivator 3 Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000209117 Panicum Species 0.000 description 2
- 235000006443 Panicum miliaceum subsp. miliaceum Nutrition 0.000 description 2
- 235000009037 Panicum miliaceum subsp. ruderale Nutrition 0.000 description 2
- 244000115721 Pennisetum typhoides Species 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 241000219833 Phaseolus Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 240000003889 Piper guineense Species 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000701507 Rice tungro bacilliform virus Species 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- 241000192584 Synechocystis Species 0.000 description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
- 241000254109 Tenebrio molitor Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 235000010749 Vicia faba Nutrition 0.000 description 2
- 240000006677 Vicia faba Species 0.000 description 2
- 235000002098 Vicia faba var. major Nutrition 0.000 description 2
- 244000042295 Vigna mungo Species 0.000 description 2
- 235000006085 Vigna mungo var mungo Nutrition 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 150000002061 ecdysteroids Chemical class 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 238000012188 high-throughput screening assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108010058731 nopaline synthase Proteins 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000004161 plant tissue culture Methods 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000015136 pumpkin Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 235000020354 squash Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- ZRUCYBDNMKWMBO-UHFFFAOYSA-N 3,5-ditert-butyl-4-hydroxy-n-(2-methylpropyl)benzamide Chemical compound CC(C)CNC(=O)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 ZRUCYBDNMKWMBO-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- DTHRMEYEJGYKKG-UHFFFAOYSA-N Ajugoside Natural products CC(=O)OC1(C)CC(O)C2C=COC(OC3OC(CO)C(O)C(O)C3O)C12C DTHRMEYEJGYKKG-UHFFFAOYSA-N 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 1
- 241000238679 Amblyomma Species 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 101100288313 Arabidopsis thaliana KTI4 gene Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 101150033765 BAG1 gene Proteins 0.000 description 1
- 108700034663 BCL2-associated athanogene 1 Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108020004998 Chloroplast DNA Proteins 0.000 description 1
- 101100209342 Choristoneura fumiferana USP gene Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108700024791 Drosophila USP Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101100209344 Drosophila melanogaster usp gene Proteins 0.000 description 1
- 101150103152 ECR gene Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 description 1
- 101000974343 Homo sapiens Nuclear receptor coactivator 4 Proteins 0.000 description 1
- 101000712576 Homo sapiens Ras-related C3 botulinum toxin substrate 3 Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 241000202974 Methanobacterium Species 0.000 description 1
- 239000005917 Methoxyfenozide Substances 0.000 description 1
- 241000589350 Methylobacter Species 0.000 description 1
- 241000589344 Methylomonas Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
- 102000004966 Nuclear Receptor Coactivator 1 Human genes 0.000 description 1
- 102000010839 Nuclear Receptor Interacting Protein 1 Human genes 0.000 description 1
- 108010062309 Nuclear Receptor Interacting Protein 1 Proteins 0.000 description 1
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 1
- 108090001144 Nuclear receptor coactivator 2 Proteins 0.000 description 1
- 102100022927 Nuclear receptor coactivator 4 Human genes 0.000 description 1
- 102100022935 Nuclear receptor corepressor 1 Human genes 0.000 description 1
- 101710153661 Nuclear receptor corepressor 1 Proteins 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 229930186873 Ponasterone Natural products 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000192707 Synechococcus Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101150033985 TPI gene Proteins 0.000 description 1
- 101150032817 TPI1 gene Proteins 0.000 description 1
- 239000005937 Tebufenozide Substances 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000605118 Thiobacillus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000723792 Tobacco etch virus Species 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 102100022011 Transcription intermediary factor 1-alpha Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101100181311 Xenopus laevis lsm14b-a gene Proteins 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CAFTUQNGDROXEZ-XBDCZORHSA-N [(1s,4as,5r,7s,7as)-4a,5-dihydroxy-7-methyl-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-7-yl] acetate Chemical compound O([C@@H]1OC=C[C@@]2(O)[C@H](O)C[C@]([C@@H]12)(C)OC(=O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CAFTUQNGDROXEZ-XBDCZORHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000036579 abiotic stress Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- CAFTUQNGDROXEZ-UHFFFAOYSA-N acetyl harpagide Natural products C12C(OC(=O)C)(C)CC(O)C2(O)C=COC1OC1OC(CO)C(O)C(O)C1O CAFTUQNGDROXEZ-UHFFFAOYSA-N 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- UCOHKZKRNWNULS-UHFFFAOYSA-N aminocyanamide Chemical class NNC#N UCOHKZKRNWNULS-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229930002869 chlorophyll b Natural products 0.000 description 1
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000008037 diacylhydrazines Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 150000002058 ecdysones Chemical class 0.000 description 1
- 108010010918 ecdysteroid receptor Proteins 0.000 description 1
- 230000000464 effect on transcription Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 101150107963 eno gene Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002428 insect molting hormone Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000002949 juvenile hormone Substances 0.000 description 1
- 229930014550 juvenile hormone Natural products 0.000 description 1
- 150000003633 juvenile hormone derivatives Chemical class 0.000 description 1
- 229930191400 juvenile hormones Natural products 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010083942 mannopine synthase Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108091008569 nuclear steroid hormone receptors Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 150000003102 ponasterones Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000021918 systemic acquired resistance Effects 0.000 description 1
- QYPNKSZPJQQLRK-UHFFFAOYSA-N tebufenozide Chemical compound C1=CC(CC)=CC=C1C(=O)NN(C(C)(C)C)C(=O)C1=CC(C)=CC(C)=C1 QYPNKSZPJQQLRK-UHFFFAOYSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108010071511 transcriptional intermediary factor 1 Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Description
NOVEL ECDYSONE RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM
This application claims priority to co-pending US provisional appUcation Serial number 60/191,355, filed March 22, 2000 and to co-pending US provisional appUcation Serial number 60/269,799, filed February 20, 2001.
FIELD OF THE INVENTION
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host ceU using this inducible gene expression system.
BACKGROUND OF THE INVENTION
In the field of genetic engineering, precise control of gene expression is a valuable tool for studying, manipulating, and continuing development and other physiological processes. Gene expression is a complex biological process involving a number of specific protein-protein interactions. In order for gene expression to be triggered, such that it produces the RNA necessary as the first step in protein synthesis, a transcriptional activator must be brought into proximity of a promoter that controls gene transcription. TypicaUy, the transcriptional activator itself is associated with a protein that has at least one DNA binding domain that binds to DNA binding sites present in the promoter regions of genes. Thus, for gene expression to occur, a protein comprising a DNA binding domain and a transactivation domain located at an appropriate distance from the DNA binding domain must be brought into the correct position in the promoter region of the gene.
The traditional transgenic approach utilizes a cell-type specific promoter to drive the expression of a designed transgene. A DNA construct containing the transgene is first incorporated into a host genome. When triggered by a transcriptional activator, expression of the transgene occurs in a given cell type.
Another means to regulate expression of foreign genes in ceUs is through inducible promoters. Examples of the use of such inducible promoters include the PRl-a promoter, prokaryotic repressor-operator systems, iinniunosuppressive-immunophilin systems, and higher
eukaryotic transcription activation systems such as steroid hormone receptor systems and are described below.
The PRl-a promoter from tobacco is induced during the systemic acquired resistance response following pathogen attack. The use of PRl-a may be Umited because it often responds to endogenous materials and external factors such as pathogens, UV-B radiation, and poUutants. Gene regulation systems based on promoters induced by heat shock, interferon and heavy metals have been described (Wurn et al., 1986, Proc. Natl. Acad. Sci. USA 83:5414- 5418; Arnheiter et al., 1990 Cell 62:51-61; Filmus et al., 1992 Nucleic Acids Research 20:27550-27560). However, these systems have limitations due to their effect on expression of non-target genes. These systems are also leaky.
Prokaryotic repressor-operator systems utilize bacterial repressor proteins and the unique operator DNA sequences to which they bind. Both the tetracycline ("Tet") and lactose ("Lac") repressor-operator systems from the bacterium Escherichia coli have been used in plants and animals to control gene expression. In the Tet system, tetracycline binds to the TetR repressor protein, resulting in a conformational change which releases the repressor protein from the operator which as a result allows transcription to occur. In the Lac system, a lac operon is activated in response to the presence of lactose, or synthetic analogs such as isopropyl-b-D-thiogalactoside. Unfortunately, the use of such systems is restricted by unstable chemistry of the Ugands, i.e. tetracycUne and lactose, their toxicity, their natural presence, or the relatively high levels required for induction or repression. For similar reasons, utility of such systems in animals is limited. hnmunosuppressive molecules such as FK506, rapamycin and cyclosporine A can bind to immunophilins FKBP12, cyclophiUn, etc. Using this information, a general strategy has been devised to bring together any two proteins simply by placing FK506 on each of the two proteins or by placing FK506 on one and cyclosporine A on another one. A synthetic homodimer of FK506 (FK1012) or a compound resulted from fusion of FK506-cyclosporine (FKCsA) can then be used to induce dimerization of these molecules (Spencer et al., 1993, Science 262: 1019-24; Belshaw et al., 1996 Proc Natl Acad Sci USA 93:4604-7). Gal4 DNA binding domain fused to FKBP12 and VP16 activator domain fused to cyclophiUn, and FKCsA compound were used to show heterodimerization and activation of a reporter gene under the control of a promoter containing Gal4 binding sites. Unfortunately, this system includes immunosuppressants that can have unwanted side effects and therefore, limits its use for various mammalian gene switch appUcations.
Higher eukaryotic transcription activation systems such as steroid hormone receptor systems have also been employed. Steroid hormone receptors are members of the nuclear receptor superfamily and are found in vertebrate and invertebrate ceUs. Unfortunately, use of steroidal compounds that activate the receptors for the regulation of gene expression, particularly in plants and mammals, is limited due to their involvement in many other natural biological pathways in such organisms. In order to overcome such difficulties, an alternative system has been developed using insect ecdysone receptors (EcR).
Growth, molting, and development in insects are regulated by the ecdysone steroid hormone (molting hormone) and the juvenile hormones (Dhadialla, et al., 1998. Annu. Rev. Entomol. 43: 545-569). The molecular target for ecdysone in insects consists of at least ecdysone receptor (EcR) and ultraspiracle protein (USP). EcR is a member of the nuclear steroid receptor super family that is characterized by signature DNA and ligand binding domains, and an activation domain (KoeUe et al. 1991, Cell, 67:59-77). EcR receptors are responsive to a number of steroidal compounds such as ponasterone A and muristerone A. Recently, non-steroidal compounds with ecdysteroid agonist activity have been described, including the commerciaUy available insecticides tebufenozide and methoxyfenozide that are marketed world wide by Rohm and Haas Company (see International Patent Application No. PCT/EP96/00686 and US Patent 5,530,028). Both analogs have exceptional safety profiles to other organisms. International Patent Application No. PCT/US97/05330 (WO 97/38117) discloses methods for modulating the expression of an exogenous gene in which a DNA construct comprising the exogenous gene and an ecdysone response element is activated by a second DNA construct comprising an ecdysone receptor that, in the presence of a ligand therefor, and optionaUy in the presence of a receptor capable of acting as a silent partner, binds to the ecdysone response element to induce gene expression. The ecdysone receptor of choice was isolated from Drosophila melanogaster. TypicaUy, such systems require the presence of the silent partner, preferably retinoid X receptor (RXR), in order to provide optimum activation. In mammalian cells, insect ecdysone receptor (EcR) heterodimerizes with retinoid X receptor (RXR) and regulates expression of target genes in a ligand dependent manner. International Patent AppUcation No. PCT/US98/14215 (WO 99/02683) discloses that the ecdysone receptor isolated from the silk moth Bombyx mori is functional in mammaUan systems without the need for an exogenous dimer partner.
U.S. Patent No. 5,880,333 discloses a Drosophila melanogaster EcR and ultraspiracle
(USP) heterodimer system used in plants in which the transactivation domain and the DNA binding domain are positioned on two different hybrid proteins. Unfortunately, this system is not effective for inducing reporter gene expression in animal cells (for comparison, see Example 1.2, below). In each of these cases, the transactivation domain and the DNA binding domain (either as native EcR as in International Patent Application No. PCT/US98/14215 or as modified EcR as in International Patent Application No. PCT/US97/05330) were incorporated into a single molecule and the other heterodimeric partners, either USP or RXR, were used in their native state. Drawbacks of the above described EcR-based gene regulation systems include a considerable background activity in the absence of Ugands and that these systems are not applicable for use in both plants and animals (see U.S. Patent No. 5,880,333). For most appUcations that rely on modulating gene expression, these EcR-based systems are undesirable. Therefore, a need exists in the art for improved systems to precisely modulate the expression of exogenous genes in both plants and animals. Such improved systems would be useful for appUcations such as gene therapy, large scale production of proteins and antibodies, ceU-based high throughput screening assays, functional genomics and regulation of traits in transgenic animals. Improved systems that are simple, compact, and dependent on Ugands that are relatively inexpensive, readily available, and of low toxicity to the host would prove useful for regulating biological systems.
Various pubUcations are cited herein, the disclosures of which are incorporated by reference in their entireties. However, the citation of any reference herein should not be construed as an admission that such reference is available as "Prior Art" to the instant application.
SUMMARY OF THE INVENTION
The present invention relates to a novel ecdysone receptor-based inducible gene expression system, novel receptor polynucleotides and polypeptides for use in the novel inducible gene expression system, and methods of modulating the expression q£ a gene within a host ceU using this inducible gene expression system. In particular, Applicants' invention relates to an improved gene expression modulation system comprising a polynucleotide encoding a receptor polypeptide comprising a truncation mutation.
SpecificaUy, the present invention relates to a gene expression modulation system comprising: a) a first gene expression cassette that is capable of being expressed in a host cell comprising a polynucleotide that encodes a first polypeptide comprising: i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and u) a Ugand binding domain comprising a Ugand binding domain from a nuclear receptor; and b) a second gene expression cassette that is capable of being expressed in the host ceU comprising a polynucleotide sequence that encodes a second polypeptide comprising: i) a transactivation domain; and U) a ligand bmding domain comprising a Ugand binding domain from a nuclear receptor other than an ultraspiracle receptor; wherein the DNA binding domain and the transactivation domain are from a polypeptide other than an ecdysone receptor, a retinoid X receptor, or an ultraspiracle receptor; wherein the Ugand binding domains from the first polypeptide and the second polypeptide are different and dimerize.
In a specific embodiment, the Ugand binding domain of the first polypeptide comprises an ecdysone receptor (EcR) Ugand binding domain In another specific embodiment, the ligand binding domain of the second polypeptide comprises a retinoid X receptor (RXR) ligand binding domain.
In a preferred embodiment, the ligand binding domain of the first polypeptide comprises an ecdysone receptor Ugand binding domain and the Ugand binding domain of the second polypeptide comprises a retinoid X receptor Ugand binding domain The present invention also relates to a gene expression modulation system according to the invention further comprising c) a third gene expression cassette comprising: i) a response element to which the DNA-binding domain of the first polypeptide binds ; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and in) the gene whose expression is to be modulated. The present invention also relates to an isolated polynucleotide encoding a truncated
EcR or a truncated RXR polypeptide, wherein the truncation mutation affects ligand binding activity or ligand sensitivity.
In particular, the present invention relates to an isolated polynucleotide encoding a truncated EcR or a truncated RXR polypeptide comprising a truncation mutation that reduces ligand binding activity or Ugand sensitivity of said EcR or RXR polypeptide. In a specific embodiment, the present invention relates to an isolated polynucleotide encoding a truncated EcR or a truncated RXR polypeptide comprising a truncation mutation that reduces steroid binding activity or steroid sensitivity of said EcR or RXR polypeptide. In another specific
embodiment, the present invention relates to an isolated polynucleotide encoding a truncated EcR or a truncated RXR polypeptide comprising a truncation mutation that reduces non- steroid binding activity or non-steroid sensitivity of said EcR or RXR polypeptide.
The present invention also relates to an isolated polynucleotide encoding a truncated EcR or a truncated RXR polypeptide comprising a truncation mutation that enhances Ugand binding activity or Ugand sensitivity of said EcR or RXR polypeptide. In a specific embodiment, the present invention relates to an isolated polynucleotide encoding a trancated EcR or a truncated RXR polypeptide comprising a truncation mutation that enhances steroid binding activity or steroid sensitivity of said EcR or RXR polypeptide. In another specific embodiment, the present invention relates to an isolated polynucleotide encoding a truncated EcR or a truncated RXR polypeptide comprising a truncation mutation that enhances non- steroid binding activity or non-steroid sensitivity of said EcR or RXR polypeptide.
The present invention also relates to an isolated polynucleotide encoding a trancated RXR polypeptide comprising a truncation mutation that increases Ugand sensitivity of a heterodimer comprising the trancated retinoid X receptor polypeptide and a dimerization partner. In a specific embodiment, the dimerization partner is an ecdysone receptor polypeptide.
The present invention also relates to an isolated polypeptide encoded by a polynucleotide according to AppUcants' invention. In particular, the present invention relates to an isolated truncated EcR or truncated RXR polypeptide comprising a truncation mutation, wherein the EcR or RXR polypeptide is encoded by a polynucleotide according to the invention.
Thus, the present invention also relates to an isolated truncated EcR or trancated RXR polypeptide comprising a truncation mutation that affects Ugand binding activity or Ugand sensitivity of said EcR or RXR polypeptide.
Applicants' invention also relates to methods of modulating gene expression in a host cell using a gene expression modulation system according to the invention. SpecificaUy, Applicants' invention provides a method of modulating the expression of a gene in a host cell comprising the gene to be modulated comprising the steps of: a) introducing into the host cell a gene expression modulation system according to the invention; and b) introducing into the host cell a Ugand that independently combines with the ligand binding domains of the first polypeptide and the second polypeptide of the gene expression modulation system; wherein the gene to be expressed is a component of a chimeric gene comprising: i) a response element
comprising a domain to which the DNA binding domain from the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and in) the gene whose expression is to be modulated, whereby a complex is formed comprising the Ugand, the first polypeptide, and the second polypeptide, and whereby the complex modulates expression of the gene in the host ceU.
Applicants' invention also provides an isolated host ceU comprising an inducible gene expression system according to the invention. The present invention also relates to an isolated host ceU comprising a polynucleotide or polypeptide according to the invention. Accordingly, Applicants' invention also relates to a non-human organism comprising a host ceU according to the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 : An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a Gal4DBD-CfEcRDEF chimeric polypeptide and a second gene expression cassette encoding a VP16AD-MmRXRDEF chimeric polypeptide; prepared as described in Example 1 (switch 1.1).
Figure 2: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a Gal4DBD-CfEcRDEF chimeric polypeptide and a second gene expression cassette encoding a VPlόAD-CfUSPDEF chimeric polypeptide; prepared as described in Example 1 (switch 1.2). Figure 3: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a Gal4DBD-MmRXRDEF chimeric polypeptide and a second gene expression cassette encoding a VP16AD-CfEcRCDEF chimeric polypeptide; prepared as described in Example 1 (switch 1.3). Figure 4: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a Gal4DBD-MmRXRDEF chimeric polypeptide and a second gene expression cassette encoding a VP16AD-DmEcRCDEF chimeric polypeptide; prepared as described in Example 1 (switch 1.4).
Figure 5: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a Gal4DBD-CfUSPDEF chimeric polypeptide and a second gene expression cassette encoding a VP16AD-CfEcRCDEF chimeric polypeptide; prepared as described in Example 1 (switch 1.5).
Figure 6: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a Gal4DBD-Cf__cRDEF-VP16AD chimeric polypeptide; prepared as described in Example 1 (switch 1.6). Figure 7: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a VP16AD-CfEcRCDEF chimeric polypeptide; prepared as described in Example 1 (switch 1.7).
Figure 8: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a VP16AD-DmEcRCDEF chimeric polypeptide and a second gene expression cassette encoding a MmRXR polypeptide; prepared as described in Example 1
(switch 1.8).
Figure 9: An ecdysone receptor-based gene expression system comprising a first gene expression cassette encoding a VP16AD-CfEcRCDEF chimeric polypeptide and a second gene expression cassette encoding a MmRXR polypeptide; prepared as described in Example 1 (switch 1.9). Figure 10: An ecdysone receptor-based gene expression system comprising a gene expression cassette encoding a Gal4DBD-CfEcRCDEF chimeric polypeptide; prepared as described in Example 1 (switch 1.10).
Figure 11: Expression data of GAL4CfEcRA BCDEF, GA CfEcRCDEF, GAL4CfEcRl/2CDEF, GAL4CfEcRDEF, GAL4CfficREF, GAL4CfEcRDE truncation mutants tiransfected into NIH3T3 ceUs along with VP16MmRXRDE, pFRLUc and pTKRL plasmid DNAs.
Figure 12: Expression data of GAL4CfEcRA BCDEF, GA CfEcRCDEF, GAL4CfEcRl/2CDEF, GAL4CfEcRDEF, GAL4CfEcREF, GAL4CfEcRDE truncation mutants tiransfected into 3T3 ceUs along with VPlόMmRXRE, pFRLUc and pTKRL plasmid DNAs.
Figure 13: Expression data of VP16MmRXRA/BCDEF, VPlόMmRXRCDEF, VP16MmRXRDEF, VP16MmRXREF, VP16MmRXRBam-EF, VP16MmRXRAF2del constructs tiransfected into NIH3T3 cells along with GAL4CfEcRCDEF, pFRLUc and pTKRL plasmid DNAs. Figure 14: Expression data of VP16MmRXRA/BCDEF, VPlόMmRXRCDEF,
VP16MmRXRDEF, VP16MmRXREF, VP16MmRXRBam-EF, VP16MmRXRAF2del constructs tiransfected into NIH3T3 ceUs along with GAL4CfEcRDEF, pFRLUc and pTKRL plasmid DNAs. Figure 15: Expression data of various trancated CfEcR and MmRXR receptor pairs fransfected into NIH3T3 cells along with GAL4CfEcRDEF, pFRLUc and pTKRL plasmid
DNAs.
DETAILED DESCRIPTION OF THE INVENTION
AppUcants have now developed an improved ecdysone receptor-basedinducible gene expression system comprising a truncation mutant of an ecdysone receptor or a retinoid X receptor (RXR) polypeptide that affects Ugand binding activity or ligand sensitivity. This mutational effect may increase or reduce ligand binding activity or ligand sensitivity and may
be steroid or non-steroid specific. Thus, AppUcants' invention provides an improved ecdysone receptor-based inducible gene expression system useful for modulating expression of a gene of interest in a host ceU. In a particularly desirable embodiment, AppUcants' invention provides an inducible gene expression system that has a reduced level of background gene expression and responds to submicromolar concentrations of non-steroidal Ugand. Thus, AppUcants' novel inducible gene expression system and its use in methods of modulating gene expression in a host cell overcome the Umitations of currently available inducible expression systems and provide the skilled artisan with an effective means to control gene expression.
The present invention provides a novel inducible gene expression system that can be used to modulate gene expression in both prokaryotic and eukaryotic host cells. AppUcants' invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, ceU-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
DEFINITIONS
In this disclosure, a number of terms and abbreviations are used. The foUowing definitions are provided and should be helpful in understanding the scope and practice of the present invention.
In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%, more preferably within 5%, and even more preferably within 1 % of a given value or range.
The term "substantiaUy free" means that a composition comprising "A" (where "A" is a single protein, DNA molecule, vector, recombinanthost cell, etc.) is substantiaUy free of "B" (where "B" comprises one or more contaminating proteins, DNA molecules, vectors, etc.) when at least about 75% by weight of the proteins, DNA, vectors (depending on the category of species to which A and B belong) in the composition is "A". Preferably, "A" comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by weight. It is also preferred that a composition, which is substantiaUy free of contamination, contain only a single molecular weight species having the activity or characteristic of the species of interest. ^
The term "isolated" for the purposes of the present invention designates a biological material (nucleic acid or protein) that has been removed from its original environment (the environment in which it is naturally present).
For example, a polynucleotide present in the natural state in a plant or an animal is not isolated. The same polynucleotide separated from the adjacent nucleic acids in which it is naturaUy present. The term "purified" does not require the material to be present in a form exhibiting absolute purity, exclusive of the presence of other compounds. It is rather a relative definition.
A polynucleotide is in the "purified" state after purification of the starting material or of the natural material by at least one order of magnitude, preferably 2 or 3 and preferably 4 or 5 orders of magnitude.
A "nucleic acid" is a polymeric compound comprised of covalently Uhked subunits called nucleotides. Nucleic acid includes polyribonucleic acid (RNA) and polydeoxyribonucleic acid (DNA), both of which may be single-stranded or double-stranded. DNA includes but is not limited to cDNA, genomic DNA, plasmids DNA, synthetic DNA, and semi-synthetic DNA. DNA may be Unear, circular, or supercoiled.
A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester anologs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA- DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double- stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the non-transcribed strand of DNA (i. e. , the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.
The term "fragment" will be understood to mean a nucleotide sequence of reduced length relative to the reference nucleic acid and comprising, over the common portion, a nucleotide sequence identical to the reference nucleic acid. Such a nucleic aci l. fragment according to the invention may be, where appropriate, included in a larger polynucleotide of which it is a constituent. Such fragments comprise, or alternatively consist of, oligonucleotides ranging in length from at least 8, 10, 12, 15, 18, 20 to 25, 30, 40, 50, 70, 80, 100, 200, 500,
1000 or 1500 consecutive nucleotides of a nucleic acid according to the invention.
As used herein, an "isolated nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.
A "gene" refers to an assembly of nucleotides that encode a polypeptide, and includes cDNA and genomic DNA nucleic acids. "Gene" also refers to a nucleic acid fragment that expresses a specific protein or polypeptide, including regulatory sequences preceding (5' non- coding sequences) and foUowing (3* non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers to any gene that is not a native gene, comprising regulatory and/or coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. A chimeric gene may comprise coding sequences derived from different sources and/or regulatory sequences derived from different sources. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene or "heterologous" gene refers to a gene not normaUy found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.
"Heterologous" DNA refers to DNA not naturaUy located in the ceU, or in a chromosomal site of the ceU. Preferably, the heterologous DNA includes a gene foreign to the ceU. The term "genome" includes chromosomal as well as mitochondrial, chloroplast and viral DNA or RNA.
A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al, 1989 infra). Hybridization and washing conditions are weU known and exempUfied in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1989), particularly Chapter 11 and Table 11.1 therein (entirely
incorporated herein by reference). The conditions of temperature and ionic strength determine the "stringency" of the hybridization.
Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that dupUcate functional enzymes from closely related organisms. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a Tm of 55°, can be used, e.g., 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5x SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher Tm, e.g., 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond to the highest Tm, e. g. , 50% formamide, 5x or 6x SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible.
The term "complementary" is used to describe the relationship between nucleotide bases that are capable of hybridizing to one another. For example, with respect to DNA, adenosine is complementary to thymine and cytosine is complementary to guanine. Accordingly, the instant invention also includes isolated nucleic acid fragments that are complementary to the complete sequences as disclosed or used herein as well as those substantiaUy similar nucleic acid sequences.
In a specific embodiment, the term "standard hybridization conditions" refers to a Tm of 55°C, and utilizes conditions as set forth above. In a preferred embodiment, the Tm is 60°C; in a more preferred embodiment, the Tm is 65°C.
Post-hybridization washes also determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 minutes (min), then repeated with 2X SSC, 0.5% SDS at 45°C for 30 minutes, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 minutes. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0. IX SSC, 0.1 % SDS at 65°C. Hybridization requires that the two nucleic acids comprise complementary sequences, although depending on the stringency of the hybridation, mismatches between bases are possible.
The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables weU known in the art. The greater
the degree of similarity or homology between two nucleotide sequences, the greater the value of Tm for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher Tm) of nucleic acid hybridizations decreases in the foUowing order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating Tm have been derived (see Sambrook et al., supra, 9.50-0.51). For hybridization with shorter nucleic acids, i.e., oUgonucleotides, the position of mismatches becomes more important, and the length of the oUgonucleotide determines its specificity (see Sambrook et al., supra, 11.7-11.8).
In one embodiment the length for a hybridizable nucleic acid is at least about 10 nucleotides. Preferable a minimum length for a hybridizable nucleic acid is at least about
15 nucleotides; more preferably at least about 20 nucleotides; and most preferably the length is at least 30 nucleotides. Furthermore, the skilled artisan wiU recognize that the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the probe. The term "probe" refers to a single-stranded nucleic acid molecule that can base pair with a complementary single stranded target nucleic acid to form a double-stranded molecule.
As used herein, the term "oUgonucleotide" refers to a nucleic acid, generaUy of at least 18 nucleotides, that is hybridizable to a genomic DNA molecule, a cDNA molecule, a plasmid DNA or an mRNA molecule. OUgonucleotides can be labeled, e. g. , with 32P-nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated. A labeled oUgonucleotide can be used as a probe to detect the presence of a nucleic acid. OUgonucleotides (one or both of which may be labeled) can be used as PCR primers, either for cloning fuU length or a fragment of a nucleic acid, or to detect the presence of a nucleic acid. An oUgonucleotide can also be used to form a triple helix with a DNA molecule. GeneraUy, oUgonucleotides are prepared syntheticaUy, preferably on a nucleic acid synthesizer.
Accordingly, oUgonucleotides can be prepared with non-naturaUy occurring phosphoester analog bonds, such as thioester bonds, etc.
A "primer" is an oUgonucleotide that hybridizes to a target nucleic acid sequence to create a double stranded nucleic acid region that can serve as an initiation point for DNA synthesis under suitable conditions. Such primers may be used in a polymera§_? chain reaction.
"Polymerase chain reaction" is abbreviated PCR and means an in vitro method for enzymatically ampUfying specific nucleic acid sequences. PCR involves a repetitive series of temperature cycles with each cycle comprising three stages: denaturation of the template
nucleic acid to separate the strands of the target molecule, annealing a single stranded PCR oUgonucleotide primer to the template nucleic acid, and extension of the annealed primer(s) by DNA polymerase. PCR provides a means to detect the presence of the target molecule and, under quantitative or semi-quantitative conditions, to determine the relative amount of that target molecule within the starting pool of nucleic acids.
"Reverse transcription-polymerase chain reaction" is abbreviated RT-PCR and means an in vitro method for enzymatically producing a target cDNA molecule or molecules from an RNA molecule or molecules, foUowed by enzymatic ampUfication of a specific nucleic acid sequence or sequences within the target cDNA molecule or molecules as described above. RT- PCR also provides a means to detect the presence of the target molecule and, under quantitative or semi-quantitative conditions, to determine the relative amount of that target molecule within the starting pool of nucleic acids.
A DNA "coding sequence" is a double-stranded DNA sequence that is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. "Suitable regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing site, effector binding site and stem-loop structure. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) teirminus. A coding sequence can include, but is not Umited to, prokaryotic sequences, cDNA frommRNA, genomic DNA sequences, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usuaUy be located 3 ' to the coding sequence.
"Open reading frame" is abbreviated ORF and means a length of nucleic acid sequence, either DNA, cDNA or RNA, that comprises a translation start signal or initiation codon, such as an ATG or AUG, and a termination codon and can be potentially translated into a polypeptide sequence. ^
The term "head-to-head" is used herein to describe the orientation of two polynucleotide sequences in relation to each other. Two polynucleotides are positioned in a head-to-head orientation when the 5' end of the coding strand of one polynucleotide is adjacent
to the 5' end of the coding strand of the other polynucleotide, whereby the direction of transcription of each polynucleotide proceeds away from the 5' end of the other polynucleotide. The term "head-to-head" may be abbreviated (5')-to-(5') and may also be indicated by the symbols (<- →) or (3'<-5'5'→3'). The term "tail-to-tail" is used herein to describe the orientation of two polynucleotide sequences in relation to each other. Two polynucleotides are positioned in a tail-to-tail orientation when the 3' end of the coding strand of one polynucleotide is adjacent to the 3' end of the coding strand of the other polynucleotide, whereby the direction of transcription of each polynucleotide proceeds toward the other polynucleotide. The term "tail-to-tail" may be abbreviated (3')-to-(3') and may also be indicated by the symbols (→ <— ) or (5'— >3'3'<— 5'). The term "head-to-tail" is used herein to describe the orientation of two polynucleotide sequences in relation to each other. Two polynucleotides are positioned in a head-to-tail orientation when the 5' end of the coding strand of one polynucleotide is adjacent to the 3' end of the coding strand of the other polynucleotide, whereby the direction of transcription of each polynucleotide proceeds in the same direction as that of the other polynucleotide. The term "head-to-tail" may be abbreviated (5')-to-(3') and may also be indicated by the symbols (— >
→) or (5'→3'5'→3').
The term "downstream" refers to a nucleotide sequence that is located 3' to reference nucleotide sequence. In particular, downstream nucleotide sequences generally relate to sequences that follow the starting point of transcription. For example, the translation initiation codon of a gene is located downstream of the start site of transcription.
The term "upstream" refers to a nucleotide sequence that is located 5' to reference nucleotide sequence. In particular, upstream nucleotide sequences generally relate to sequences that are located on the 5' side of a coding sequence or starting point of transcription. For example, most promoters are located upstream of the start site of transcription.
The terms "restriction endonuclease" and "restriction enzyme" refer to an enzyme that binds and cuts within a specific nucleotide sequence within double stranded DNA.
"Homologous recombination" refers to the insertion of a foreign DNA sequence into another DNA molecule, e.g., insertion of a vector in a chromosome. Preferably, the vector targets a specific chromosomal site for homologous recombination. For specific homologous recombination, the vector wiU contain sufficiently long regions of homology to sequences of the chromosome to aUow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may
increase the efficiency of homologous recombination.
Several methods known in the art may be used to propagate a polynucleotide according to the invention. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As described herein, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adeno virus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
A "vector" is any means for the cloning of and/or transfer of a nucleic acid into a host ceU. A vector may be a repUcon to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "repUcon" is any genetic element (e.g., plasmid, phage, cosmid, chromosome, virus) that functions as an autonomous unit of DNA repUcation in vivo, i.e., capable of replication under its own control. The term "vector" includes both viral and nonviral means for introducing the nucleic acid into a cell in vitro, ex vivo or in vivo. A large number of vectors known in the art may be used to manipulate nucleic acids, incorporate response elements and promoters into genes, etc. Possible vectors include, for example, plasmids or modified viruses including, for example bacteriophages such as lambda derivatives, or plasmids such as PBR322 or pUC plasmid derivatives, or the Bluescript vector. For example, the insertion of the DNA fragments corresponding to response elements and promoters into a suitable vector can be accomplished by ligating the appropriate DNA fragments into a chosen vector that has complementary cohesive termini. Alternatively, the ends of the DNA molecules may be enzymatically modified or any site may be produced by ligating nucleotide sequences (linkers) into the DNA termini. Such vectors may be engineered to contain selectable marker genes that provide for the selection of cells that have incorporated the marker into the ceUular genome. Such markers aUo w identification and/or selection of host ceUs that incorporate and express the proteins encoded by the marker.
Viral vectors, and particularly retroviral vectors, have been used in a wide variety of gene deUvery applications in cells, as well as Uving animal subjects. Viral vectors that can be used include but are not United to retrovirus, adeno-associated virus, pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr, adeno virus, geminiviras, and caulimoyjrus vectors.
Non-viral vectors include plasmids, liposomes, electricaUy charged Upids (cytofectins), DNA- protein complexes, and biopolymers. In addition to a nucleic acid, a vector may also comprise one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and
monitoring nucleic acid transfer results (transfer to which tissues, duration of expression, etc.). The term "plasmid" refers to an extra chromosomal element often carrying a gene that is not part of the central metaboUsm of the ceU, and usuaUy in the form of circular double- stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear, circular, or supercoiled, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a ceU. A "cloning vector" is a "repUcon", which is a unit length of a nucleic acid, preferably
DNA, that replicates sequentially and which comprises an origin of repUcation, such as a plasmid, phage or cosmid, to which another nucleic acid segment may be attached so as to bring about the repUcation of the attached segment. Cloning vectors may be capable of repUcation in one cell type and expression in another ("shuttle vector"). Vectors may be introduced into the desired host ceUs by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, e.g., Wu et al., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem 263:14621-14624; and Hartmut et al., Canadian Patent AppUcation No. 2,012,311, filed March 15, 1990).
A polynucleotide according to the invention can also be introduced in vivo by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of nucleic acids in vitro. Synthetic cationic Upids designed to limit the difficulties and dangers encountered with Uposome mediated transfection can be used to prepare liposomes for in vivo transfection of a gene encoding a marker (Feigner et al., 1987. PNAS 84:7413; Mackey, et al.,
1988. Proc. Natl. Acad. Sci. U.S.A 85:8027-8031; and Ulmer et al., 1993. Science 259:1745- 1748). The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged ceU membranes (Feigner and Ringold, 1989. Science 337:387-388). Particularly useful Upid compounds and compositions for transfer of nucleic acids are described in International Patent PubUcations W095/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. The use of lipofection to introduce exogenous genes into the specific organs in vivo has certain practical advantages. Molecular targeting of liposomes to specific ceUs represents one area of benefit. It is clear that directing transfection to particular ceU
types would be particularly preferred in a tissue with cellular heterogeneity, such as pancreas, Uver, kidney, and the brain. Lipids may be chemically coupled to other molecules for the purpose of targeting (Mackey, et al., 1988, supra). Targeted peptides, e.g., hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to Uposomes chemicaUy.
Other molecules are also useful for facilitating transfection of a nucleic acid in vivo, such as a cationic oUgopeptide (e.g., WO95/21931), peptides derived from DNA binding proteins (e.g., WO96/25508), or a cationic polymer (e.g., WO95/21931).
It is also possible to introduce a vector in vivo as a naked DNA plasmid (see U.S. Patents 5,693,622, 5,589,466 and 5,580,859). Receptor-mediated DNA delivery approaches can also be used (Curiel et al., 1992. Hum Gene Ther. 3:147-154; and Wu and Wu, 1987. J. Biol. Chem 262:4429-4432).
The term "transfection" means the uptake of exogenous or heterologous RNA or DNA by a ceU. A ceU has been "transfected" by exogenous or heterologous RNA or DNA when such RNA or DNA has been introduced inside the ceU. A cell has been "transformed" by exogenous or heterologous RNA or DNA when the transfected RNA or DNA effects a phenotypic change. The transforming RNA or DNA can be integrated (covalentiy linked) into chromosomal DNA making up the genome of the ceU.
"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in geneticaUy stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" or "recombinant" or "transformed" organisms.
The term "genetic region" will refer to a region of a nucleic acid molecule or a nucleotide sequence that comprises a gene encoding a polypeptide. In addition, the recombinant vector comprising a polynucleotide according to the invention may include one or more origins for replication in the ceUular hosts in which their ampUfication or their expression is sought, markers or selectable markers.
The term "selectable marker" means an identifying factor, usuaUy an antibiotic or chemical resistance gene, that is able to be selected for based upon the marker gene's effect, i.e., resistance to an antibiotic, resistance to a herbicide, colorimetric markers, enzymes, fluorescent markers, and the like, wherein the effect is used to track the inheritance of a nucleic acid of interest and/or to identify a cell or organism that has inherited the nucleic acid of
interest. Examples of selectable marker genes known and used in the art include: genes providing resistance to ampicUUn, streptomycin, gentamycin, kanamycin, hygromycin, bialaphos herbicide, sulfonamide, and the Uke; and genes that are used as phenotypic markers, i.e., anthocyanin regulatory genes, isopentanyl transferase gene, and the like. The term "reporter gene" means a nucleic acid encoding an identifying factor that is able to be identified based upon the reporter gene's effect, wherein the effect is used to track the inheritance of a nucleic acid of interest, to identify a ceU or organism that has inherited the nucleic acid of interest, and/or to measure gene expression induction or transcription. Examples of reporter genes known and used in the art include: luciferase (Luc), green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), β-galactosidase (LacZ), β-glucuronidase (Gus), and the like. Selectable marker genes may also be considered reporter genes.
"Promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters that cause a gene to be expressed in most ceU types at most times are commonly referred to as "constitutive promoters". Promoters that cause a gene to be expressed in a specific ceU type are commonly referred to as "ceU-specific promoters" or "tissue-specific promoters". Promoters that cause a gene to be expressed at a specific stage of development or ceU differentiation are commonly referred to as "developmentaUy-specific promoters" or "cell differentiation-specific promoters". Promoters that are induced and cause a gene to be expressed foUowing exposure or treatment of the ceU with an agent, biological molecule, chemical, Ugand, Ught, or the like that induces the promoter are commonly referred to as "inducible promoters" or "regulatable promoters". It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity. A "promoter sequence" is a DNA regulatory region capable of binding- RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' teπninus by the transcription initiation site and extends upstream (5' direction) to include
the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S 1), as weU as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced (if the coding sequence contains introns) and translated into the protein encoded by the coding sequence.
"Transcriptional and translational control sequences" are DNA regulatory sequences, such as promoters, enhancers, teirrninators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.
The term "response element" means one or more cis-acting DNA elements which confer responsiveness on a promoter mediated through interaction with the DNA-binding domains of the first chimeric gene. This DNA element may be either paUndromic (perfect or imperfect) in its sequence or composed of sequence motifs or half sites separated by a variable number of nucleotides. The half sites can be similar or identical and arranged as either direct or inverted repeats or as a single half site or multimers of adjacent half sites in tandem. The response element may comprise a minimal promoter isolated from different organisms depending upon the nature of the cell or organism into which the response element wiU be incorporated. The DNA binding domain of the first hybrid protein binds, in the presence or absence of a Ugand, to the DNA sequence of a response element to initiate or suppress transcription of downstream gene(s) under the regulation of this response element. Examples of DNA sequences for response elements of the natural ecdysone receptor include: RRGG/TTCANTGAC/ACYY (see Cherbas L., et. al., (1991), Genes Dev. 5, 120-131);
AGGTCAN(„)AGGTCA, where N(n) can be one or more spacer nucleotides (see DAvino PP., et. al., (1995), Mol. Cell. Endocήnol, 113, 1-9); and GGGTTGAATGAATTT (see Antoniewski C, et. al., (1994). Mol. Cell Biol. 14, 4465-4474).
The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably Unked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in
sense or antisense orientation.
The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from a nucleic acid or polynucleotide. Expression may also refer to translation of mRNA into a protein or polypeptide.
The terms "cassette", "expression cassette" and "gene expression cassette" refer to a segment of DNA that can be inserted into a nucleic acid or polynucleotide at specific restriction sites or by homologous recombination. The segment of DNA comprises a polynucleotide that encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.
"Transformation cassette" refers to a specific vector comprising a polynucleotide that encodes a polypeptide of interest and having elements in addition to the polynucleotide that f aciUtate transformation of a particular host ceU. Cassettes, expression cassettes, gene expression cassettes and transformation cassettes of the invention may also comprise elements that aUow for enhanced expression of a polynucleotide encoding a polypeptide of interest in a host cell. These elements may include, but are not limited to: a promoter, a minimal promoter, an enhancer, a response element, a terminator sequence, a polyadenylation sequence, and the like.
For purposes of this invention, the term "gene switch" refers to the combination of a response element associated with a promoter, and an EcR based system which, in the presence of one or more Ugands, modulates the expression of a gene into which the response element and promoter are incorporated.
The terms "modulate" and "modulates" mean to induce, reduce or inhibit nucleic acid or gene expression, resulting in the respective induction, reduction or inhibition of protein or polypeptide production. The plasmids or vectors according to the invention may further comprise at least one promoter suitable for driving expression of a gene in a host ceU. The term "expression vector" means a vector, plasmid or vehicle designed to enable the expression of an inserted nucleic acid sequence foUowing transformation into the host. The cloned gene, i.e., the inserted nucleic acid sequence, is usually placed under the control of control elements such as a promoter, a minimal promoter, an enhancer, or the like. Initiation control regions or promoters, whjch are useful to drive expression of a nucleic acid in the desired host cell are numerous and famiUar to those skilled in the art. VirtuaUy any promoter capable of driving these genes is suitable for the present invention including but not limited to: viral promoters, plant promoters, bacterial
promoters, animal promoters, mammalian promoters, synthetic promoters, constitutive promoters, tissue specific promoter, developmental specific promoters, inducible promoters, light regulated promoters; CYC1, HIS3, GAL1, GALA, GAL10, ADH1, PGK, PH05, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI, alkaline phosphatase promoters (useful for expression in Saccharomyces); AOX1 promoter (useful for expression in Pichia); b-lactamase, lac, or a, tet, trp, IPjj IPR, T7, tac, and trc promoters (useful for expression in Escherichia coli); and light regulated-, seed specific-, pollen specific-, ovary specific-, pathogenesis or disease related-, cauliflower mosaic viras 35S, CMV 35S minimal, cassava vein mosaic viras (CsVMV), chlorophyll a/b binding protein, ribulose 1, 5-bisphosphate carboxylase, shoot- specific, root specific, chitinase, stress inducible, rice tungro bacUUform virus, plant super- promoter, potato leucine aminopeptidase, nitrate reductase, mannopine synthase, nopaline synthase, ubiquitin, zein protein, and anthocyanin promoters (useful for expression in plant ceUs); animal and mammaUan promoters known in the art include, but are not limited to, the SV40 early (SV40e) promoter region, the promoter contained in the 3' long terminal repeat (LTR) of Rous sarcoma virus (RSV), the promoters of the El A or major late promoter (MLP) genes of adenoviruses, the cytomegalovirus early promoter, the herpes simplex virus (HSV) thymidine kinase (TK) promoter, an elongation factor 1 alpha (EF1) promoter, a phosphoglycerate kinase (PGK) promoter, a ubiquitin (Ubc) promoter, an albumin promoter, the regulatory sequences of the mouse metallothionein-L promoter, and transcriptional control regions, the ubiquitous promoters (HPRT, vimentin, -actin, tubulin and the Uke), the promoters of the intermediate filaments (desmin, neurofilaments, keratin, GFAP, and the like), the promoters of therapeutic genes (of the MDR, CFTR or factor VIII type, and the Uke), and promoters that exhibit tissue specificity and have been utiUzed in transgenic animals, such as the elastase I gene control region which is active in pancreatic acinar cells; insuUn gene control region active in pancreatic beta cells, immunoglobulin gene control region active in lymphoid ceUs, mouse πiammary tumor virus control region active in testicular, breast, lymphoid and mast ceUs; albumin gene, Apo Al and Apo All control regions active in liver, alpha-fetoprotein gene control region active in Uver, alpha 1-antitrypsin gene control region active in the Uver, beta-globin gene control region active in myeloid ceUs, myelin basic protein gene control region active in oUgodendrocyte ceUs in the brain, myosin Ught chain-2 gene control region active in skeletal muscle, and gonadotropic releasing hormone gene control region active in the hypothalamus, pyruvate kinase promoter, vilUn promoter, promoter of the fatty acid binding intestinal protein, promoter of the smooth muscle cell α-actin, and the Uke. In a preferred
embodiment of the invention, the promoter is selected from the group consisting of a cauliflower mosaic viras 35S promoter, a cassava vein mosaic viras promoter, and a cauliflower mosaic virus 35S minimal promoter, an elongation factor 1 alpha (EF1) promoter, a phosphoglycerate kinase (PGK) promoter, a ubiquitin (Ubc) promoter, and an albumin promoter. In addition, these expression sequences may be modified by addition of enhancer or regulatory sequences and the Uke.
Enhancers that may be used in embodiments of the invention include but are not limited to: tobacco mosaic virus enhancer, cauliflower mosaic virus 35S enhancer, tobacco etch virus enhancer, ribulose 1, 5-bisphosphate carboxylase enhancer, rice tungro bacilUform viras enhancer, and other plant and viral gene enhancers, and the like.
Termination control regions, i.e., teiminator or polyadenylation sequences, may also be derived from various genes native to the preferred hosts. OptionaUy, a termination site may be unnecessary, however, it is most preferred if included. In a preferred embodiment of the invention, the termination control region may be comprise or be derived from a synthetic sequence, synthetic polyadenylation signal, an SV40 late polyadenylation signal, an SV40 polyadenylation signal, a bovine growth hormone (BGH) polyadenylation signal, nopaline synthase (nos), cauUflower mosaic virus (CaMV), octopine synthase (ocs), Agrocateum, viral, and plant terminator sequences, or the like.
The terms "3' non-coding sequences" or "3' untranslated region (UTR)" refer to DNA sequences located downstream (3') of a coding sequence and may comprise polyadenylation tpoly(A)] recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usuaUy characterized by affecting the addition of polyadenyUc acid tracts to the 3' end of the mRNA precursor. "Regulatory region" means a nucleic acid sequence which regulates the expression of a second nucleic acid sequence. A regulatory region may include sequences which are naturaUy responsible for expressing a particular nucleic acid (a homologous region) or may include sequences of a different origin that are responsible for expressing different proteins or even synthetic proteins (a heterologous region). In particular, the sequences can be sequences of prokaryotic, eukaryotic, or viral genes or derived sequences that stimulate or repress transcription of a gene in a specific or non-specific manner and in an inducible or non-inducible manner. Regulatory regions include origins of repUcation, RNA spUce sites, promoters, enhancers, transcriptional termination sequences, and signal sequences which direct the
polypeptide into the secretory pathways of the target cell.
A regulatory region from a "heterologous source" is a regulatory region that is not naturaUy associated with the expressed nucleic acid. Included among the heterologous regulatory regions are regulatory regions from a different species, regulatory regions from a different gene, hybrid regulatory sequences, and regulatory sequences which do not occur in nature, but which are designed by one having ordinary skill in the art.
"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into protein by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA refers to RNA transcript that includes the mRNA and so can be translated into protein by the cell. "Antisense RNA" refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene. The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, or the coding sequence. "Functional RNA" refers to antisense RNA, ribozyme RNA, or other RNA that is not translated yet has an effect on ceUular processes. A "polypeptide" is a polymeric compound comprised of covalently linked amino acid residues. Amino acids have the following general structure:
H
R-C-COOH ' I
NH2 Amino acids are classified into seven groups on the basis of the side chain R: (1) aUphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side chains containing a basic group, (6) side chains containing an aromatic ring, and (7) proUne, an imino acid in which the side chain is fused to the amino group. A polypeptide of the invention preferably comprises at least about 14 amino acids.
A "protein" is a polypeptide that performs a structural or functional role in a living
ceU.
An "isolated polypeptide" or "isolated protein" is a polypeptide or protein that is substantiaUy free of those compounds that are normally associated therewith in its natural state (e.g., other proteins or polypeptides, nucleic acids, carbohydrates, lipids). "Isolated" is not meant to exclude artificial or synthetic mixtures with other compounds, or the presence of impurities which do not interfere with biological activity, and which may be present, for example, due to incomplete purification, addition of stabiUzers, or compounding into a pharmaceuticaUy acceptable preparation.
"Fragment" of a polypeptide according to the invention wiU be understood to mean a polypeptide whose amino acid sequence is shorter than that of the reference polypeptide and which comprises, over the entire portion with these reference polypeptides, an identical amino acid sequence. Such fragments may, where appropriate, be included in a larger polypeptide of which they are a part. Such fragments of a polypeptide according to the invention may have a length of 10, 15, 20, 30 to 40, 50, 100, 200 or 300 amino acids. A "variant" of a polypeptide or protein is any analogue, fragment, derivative, or mutant which is derived from a polypeptide or protein and which retains at least one biological property of the polypeptide or protein. Different variants of the polypeptide or protein may exist in nature. These variants may be aUeUc variations characterized by differences in the nucleotide sequences of the structural gene coding for the protein, or may involve differential spUcing or post-translational modification. The skilled artisan can produce variants having single or multiple amino acid substitutions, deletions, additions, or replacements. These variants may include, inter alia: (a) variants in which one or more amino acid residues are substituted with conservative or non-conservative amino acids, (b) variants in which one or more amino acids are added to the polypeptide or protein, (c) variants in which one or more of the amino acids includes a substituent group, and (d) variants in which the polypeptide or protein is fused with another polypeptide such as serum albumin. The techniques for obtaining these variants, including genetic (suppressions, deletions, mutations, etc.), chemical, and enzymatic techniques, are known to persons having ordinary skill in the art. A variant polypeptide preferably comprises at least about 14 amino acids. A "heterologous protein" refers to a protein not naturaUy produced in the ceU.
A "mature protein" refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation of mRNA; i.e., with
pre- and propeptides stiU present. Pre- and propeptides may be but are not Umited to intracellular localization signals.
The term "signal peptide" refers to an amino terminal polypeptide preceding the secreted mature protein. The signal peptide is cleaved from and is therefore not present in the mature protein. Signal peptides have the function of directing and translocating secreted proteins across cell membranes. Signal peptide is also referred to as signal protein.
A "signal sequence" is included at the beginning of the coding sequence of a protein to be expressed on the surface of a ceU. This sequence encodes a signal peptide, N-teiminal to the mature polypeptide, that directs the host ceU to translocate the polypeptide. The term "translocation signal sequence" is used herein to refer to this sort of signal sequence.
Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes, and are often functional in both types of organisms.
The term "homology" refers to the percent of identity between two polynucleotide or two polypeptide moieties. The correspondence between the sequence from one moiety to anolher can be determined by techniques known to the art. For example, homology can be determined by a direct comparison of the sequence information between two polypeptide molecules by aUgning the sequence information and using readily available computer programs. Alternatively, homology can be determined by hybridization of polynucleotides under conditions that form stable duplexes between homologous regions, foUowed by digestion with single-stranded-specific nuclease(s) and size determination of the digested fragments. As used herein, the term "homologous" in aU its grammatical forms and speUing variations refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck et al., 1987, Cell 50:667.). Such proteins (and their encoding genes) have sequence homology, as reflected by their high degree of sequence similarity.
Accordingly, the term "sequence similarity" in aU its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common evolutionary origin (see Reeck et al., 1987, Cell 50:667). As used herein, the term "homologous" in aU its grammatical forms and speUύjg variations refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies and homologous proteins from different species (Reeck et al., supra). Such proteins (and their encoding genes) have sequence homology, as reflected by
their high degree of sequence similarity. However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "highly," may refer to sequence similarity and not a common evolutionary origin.
In a specific embodiment, two DNA sequences are "substantiaUy homologous" or "substantially similar" when at least about 50% (preferably at least about 75%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantiaUy homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skUl of the art. See, e.g., Sambrook et al., 1989, supra.
As used herein, "substantiaUy similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. "SubstantiaUy similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the abiUty of the nucleic acid fragment to mediate alteration of gene expression by antisense or co-suppression technology. "SubstantiaUy similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotide bases that do not substantially affect the functional properties of the resulting transcript. It is therefore understood that the invention encompasses more than the specific exemplary sequences. Each of the proposed modifications is weU within the routine skUl in the art, as is determination of retention of biological activity of the encoded products.
Moreover, the skiUed artisan recognizes that substantially similar sequences encompassed by this invention are also defined by their abiUty to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65°C and washed with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS), with the sequences exempUfied herein. SubstantiaUy similar nucleic acid fragments of the instant invention are those nucleic acid fragments whose DNA sequences are at least 70% identical to the DNA sequence of the nucleic acid fragments reported herein. Preferred substantiaUy nucleic acid fragments of the instant invention are thos^nucleic acid fragments whose DNA sequences are at least 80% identical to the DNA sequence of the nucleic acid fragments reported herein. More preferred nucleic acid fragments are at least 90% identical to the DNA sequence of the nucleic acid fragments reported herein. Even more
preferred are nucleic acid fragments that are at least 95% identical to the DNA sequence of the nucleic acid fragments reported herein.
Two amino acid sequences are "substantiaUy homologous" or "substantiaUy simUar" when greater than about 40% of the amino acids are identical, or greater than 60% are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the
GCG Package, Version 7, Madison, Wisconsin) pileup program.
The term "corresponding to" is used herein to refer to similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. A nucleic acid or amino acid sequence alignment may include spaces. Thus, the term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.
A "substantial portion" of an amino acid or nucleotide sequence comprises enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to putatively identify that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Basic Local AUgnment Search Tool; Altschul, S. F., et al, (1993) /. Mol.
Biol. 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence often or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene.
Moreover, with respect to nucleotide sequences, gene specific oUgonucleotide probes comprising 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., in situ hybridization of bacterial colonies or bacteriophage plaques). In addition, short oUgonucleotides of 12-15 bases may be used as ampUfication primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises enough of the sequence to specifically identify and/or isolate a nucleic acid fragment comprising the sequence.
The term "percent identity", as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as deterrnine^,by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "simUarity" can be readUy calculated by
known methods, including but not limited to those described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects (Smith, D. W., ed.) Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991). Preferred methods to determine identity are designed to give the best match between the sequences tested. Methods to determine identity and similarity are codified in pubUcly available computer programs. Sequence aUgnments and percent identity calculations may be performed using the Megalign program of the
LASERGENE bioinfoimatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences may be performed using the Clustal method of aUgnment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise aUgnments using the Clustal method may be selected: KTUPLE 1 , GAP PENALTY=3 , WINDOW=5 and DIAGONALS SAVED=5.
The term "sequence analysis software" refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. "Sequence analysis software" may be commercia y available or independently developed. Typical sequence analysis software wiU include but is not limited to the GCG suite of programs
(Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI), BLASTP, BLASTN, BLASTX (Altschul et al., /. Mol. Biol. 215:403-410 (1990), and DNASTAR (DNASTAR, Inc. 1228 S. Park St. Madison, WI 53715 USA). Within the context of this appUcation it wiU be understood that where sequence analysis software is used for analysis, that the results of the analysis wiU be based on the "default values" of the program referenced, unless otherwise specified. As used herein "default values" wiU mean any set of values or parameters which originaUy load with the software when first initiaUzed.
"Synthetic genes" can be assembled from oUgonucleotide buUding blocks that are chemically synthesized using procedures known to those skUled in the art. These building blocks are Ugated and annealed to form gene segments that are then enzymatiqaUy assembled to construct the entire gene. "Chemically synthesized", as related to a sequence of DNA, means that the component nucleotides were assembled in vitro. Manual chemical synthesis of DNA may be accompUshed using weU estabUshed procedures, or automated chemical synthesis can
be performed using one of a number of commercially available machines. Accordingly, the genes can be tailored for optimal gene expression based on optimization ofnucleoti.de sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host ceU where sequence information is available.
GENE EXPRESSION MODULATION SYSTEM OF THE INVENTION
AppUcants have now shown that separating the transactivation and DNA binding domains by placing them on two different proteins results in greatly reduced background activity in the absence of a Ugand and significantly increased activity over background in the presence of a ligand. AppUcants' improved gene expression system comprises two chimeric gene expression; the first encoding a DNA binding domain fused to a nuclear receptor polypeptide and the second encoding a transactivation domain fused to a nuclear receptor polypeptide. The interaction of the first protein with the second protein effectively tethers the DNA binding domain to the transactivation domain. Since the DNA binding and transactivation domains reside on two different molecules, the background activity in the absence of Ugand is greatly reduced.
In general, the inducible gene expression modulation system of the invention comprises a) a first chimeric gene that is capable of being expressed in a host ceU comprising a polynucleotide sequence that encodes a first hybrid polypeptide comprising i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and ii) a Ugand binding domain comprising the ligand binding domain from a nuclear receptor; and b) a second chimeric gene that is capable of being expressed in the host ceU comprising a polynucleotide sequence that encodes a second hybrid polypeptide comprising: i) a transactivation domain; and n) a Ugand binding domain comprising the ligand binding domain from a nuclear receptor other than ultraspiracle (USP); wherein the transactivation domain are from other than EcR, RXR, or USP; and wherein the ligand binding domains from the first hybrid polypeptide and the second hybrid polypeptide are different and dimerize. ,_,
This two-hybrid system exploits the abiUty of a pair of interacting proteins to bring the transcription activation domain into a more favorable position relative to the DNA binding domain such that when the DNA binding domain binds to the DNA binding site on the gene,
the transactivation domain more effectively activates the promoter (see, for example, U.S. Patent No. 5,283,173). This two-hybrid system is a significantly improved inducible gene expression modulation system compared to the two systems disclosed in International Patent Applications PCT/US97/05330 and PCT/US98/14215. 5 The ecdysone receptor-based gene expression modulation system of the invention may be either heterodimeric and homodimeric. A functional EcR complex generaUy refers to a heterodimeric protein complex consisting of two members of the steroid receptor family, an ecdysone receptor protein obtained from various insects, and an ultraspiracle (USP) protein or the vertebrate homolog of USP, retinoid X receptor protein (see Yao, et al. (1993) Nature 366,
10 476-479; Yao, et al., (1992) Cell 71, 63-72). However, the complex may also be a homodimer as detaUed below. The functional ecdysteroid receptor complex may also include additional protein(s) such as immunophiUns. Additional members of the steroid receptor family of proteins, known as transcriptional factors (such as DHR38 or betaFTZ-1), may also be Ugand dependent or independent partners for EcR, USP, and/or RXR. AdditionaUy, other cofactors
15 may be required such as proteins generaUy known as coactivators (also termed adapters or mediators). These proteins do not bind sequence-specificaUy to DNA and are not involved in basal transcription. They may exert their effect on transcription activation through various mechanisms, including stimulation of DNA-binding of activators, by affecting chromatin structure, or by mediating activator-initiation complex interactions. Examples of such
20 coactivators include RIP140, TIF1, RAP46/Bag-1, ARA70, SRC-l/NCoA-1,
ΗF2/GRIP/NCoA-2, ACTR/AIBl/RAC3/pCIP as weU as the promiscuous coactivator C response element B binding protein, CBP/p300 (for review see Glass et al, Curr. Opin. Cell Biol. 9:222-232, 1997). Also, protein cofactors generally known as corepressors (also known as repressors, silencers, or silencing mediators) may be required to effectively inhibit
25 transcriptional activation in the absence of ligand. These corepressors may interact with the unliganded ecdysone receptor to silence the activity at the response element. Current evidence suggests that binding of Ugand changes the conformation of the receptor, which results in release of the corepressor and recruitment of the above described coactivators, thereby . aboUshing their silencing activity. Examples of corepressors include N-CoR and SMRT (for
30 review, see Horwitz et al. Mol Endocrinol. 10: 1167-1177, 1996). These cofactors may either be endogenous within the cell or organism, or may be added exogenously as transgenes to be expressed in either a regulated or unregulated fashion. Homodimer complexes of the ecdysone receptor protein, USP, or RXR may also be functional under some circumstances.
The ecdysone receptor complex typicaUy includes proteins which are members of the nuclear receptor superfamUy wherein all members are characterized by the presence of an amino-terminal transactivation domain, a DNA binding domain ("DBD"), and a ligand binding domain ("LBD") separated from the DBD by a hinge region. As used herein, the term "DNA binding domain" comprises a niinimal peptide sequence of a DNA binding protein, up to the entire length of a DNA binding protein, so long as the DNA binding domain functions to associate with a particular response element. Members of the nuclear receptor superfamily are also characterized by the presence of four or five domains: A B, C, D, E, and in some members F (see Evans, Science 240:889-895 (1988)). The "A/B" domain corresponds to the transactivation domain, "C" corresponds to the DNA binding domain, "D" corresponds to the hinge region, and "E" corresponds to the Ugand binding domain. Some members of the family may also have another transactivation domain on the carboxy-terminal side of the LBD corresponding to "F".
The DBD is characterized by the presence of two cysteine zinc fingers between which are two amino acid motifs, the P-box and the D-box, which confer specificity for ecdysone response elements. These domains may be either native, modified, or chimeras of different domains of heterologous receptor proteins. This EcR receptor, like a subset of the steroid receptor family, also possesses less weU defined regions responsible for heterodimerization properties. Because the domains of EcR, USP, and RXR are modular in nature, the LBD, DBD, and transactivation domains may be interchanged.
Gene switch systems are known that incorporate components from the ecdysone receptor complex. However, in these known systems, whenever EcR is used it is associated with native or modified DNA binding domains and transactivation domains on the same molecule. USP or RXR are typically used as silent partners. We have now shown that when DNA binding domains and transactivation domains are on the same molecule the background activity in the absence of ligand is high and that such activity is dramaticaUy reduced when DNA binding domains and transactivation domains are on different molecules, that is, on each of two partners of a heterodimeric or homodimeric complex. This two-hybrid system also provides improved sensitivity to non-steroidal Ugands for example, diacylhydrazines, when compared to steroidal Ugands for example, ponasterone A ("PonA") or muristerone A
("MurA"). That is, when compared to steroids, the non-steroidal Ugands provide higher activity at a lower concentration. In addition, since transactivation based on EcR gene switches is often ceU-line dependent, it is easier to tailor switching system to obtain maximum
transactivation capabUity for each appUcation. Furthermore, this two-hybrid system avoids some side effects due to overexpression of RXR that often occur when unmodified RXR is used as a switching partner. In this two-hybrid system, native DNA binding and transactivation domains of EcR or RXR are eliminated. As a result, these chimeric molecules have less chance of interacting with other steroid hormone receptors present in the cell resulting in reduced side effects.
SpecificaUy, AppUcants' invention relates to a gene expression modulation system comprising: a) a first gene expression cassette that is capable of being expressed in a host ceU, wherein the first gene expression cassette comprises a polynucleotide that encodes a first polypeptide comprising i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and U) a ligand binding domain comprising a Ugand binding domain from a nuclear receptor; and b) a second gene expression cassette that is capable of being expressed in the host ceU, wherein the second gene expression cassette comprises a polynucleotide sequence that encodes a second polypeptide comprising i) a transactivation domain; and U) a ligand binding domain comprising a Ugand binding domain from a nuclear receptor other than ultraspiracle (USP); wherein the DNA binding domain and the transactivation domain are from other than EcR, RXR, or USP; wherein the ligand binding domains from the first polypeptide and the second polypeptide are different and dimerize.
The present invention also relates to a gene expression modulation system according to the present invention further comprising c) a third gene expression cassette comprising: i) the response element to which the DNA-binding domain of the first polypeptide binds; n) a promoter that is activated by the transactivation domain of the second polypeptide; and iu) the gene whose expression is to be modulated.
In a specific embodiment, the gene whose expression is to be modulated is a homologous gene with respect to the host ceU. In another specific embodiment, the gene whose expression is to be modulated is a heterologous gene with respect to the host cell.
In a specific embodiment, the Ugand binding domain of the first polypeptide comprises an ecdysone receptor ligand binding domain.
In another specific embodiment, the ligand binding domain of the first polypeptide comprises a retinoid X receptor ligand binding domain. ,_,
In a specific embodiment, the ligand binding domain of the second polypeptide comprises an ecdysone receptor Ugand binding domain.
In another specific embodiment, the ligand binding domain of the second polypeptide
comprises a retinoid X receptor ligand binding domain.
In a preferred embodiment, the ligand binding domain of the first polypeptide comprises an ecdysone receptor Ugand binding domain, and the Ugand binding domain of the second polypeptide comprises a retinoid X receptor ligand binding domain. In another preferred embodiment, the ligand binding domain of the first polypeptide is from a retinoid X receptor polypeptide, and the ligand binding domain of the second polypeptide is from an ecdysone receptor polypeptide.
Preferably, the Ugand binding domain is an EcR or RXR related steroid/thyroid hormone nuclear receptor family member ligand binding domain, or analogs, combinations, or modifications thereof. More preferably, the LBD is from EcR or RXR. Even more preferably, the LBD is from a truncated EcR or RXR. A truncation mutation may be made by any method used in the art, including but not limited to restriction endonuclease digestion/deletion, PCR-mediated/oUgonucleotide-directed deletion, chemical mutagenesis, UV strand breakage, and the like. Preferably, the EcR is an insect EcR selected from the group consisting of a
Lepidopteran EcR, a Dipteran EcR, an Arthropod EcR, a Homopteran EcR and a Hemipteran EcR. More preferably, the EcR for use is a spruce budworm Choristoneurafumiferana EcR ("CfEcR"), a Tenebrio molitor EcR ("TmEcR"), a Manduca sexta EcR ("MsEcR"), a Heliothies virescens EcR ("HvEcR"), a silk moth Bombyx mori EcR ("BmEcR"), a fruit fly Drosophila melanogaster EcR ("DmEcR"), a mosquito Aedes aegypti EcR ("AaEcR"), a blowfly LuciUa capitata EcR ("LcEcR"), a Mediterranean fruit fly Ceratitis capitata EcR ("CcEcR"), a locust Locusta migratoria EcR ("LmEcR"), an aphid Myzus persicae EcR ("MpEcR"), a fiddler crab Uca pugilator EcR ("UpEcR"), or an ixodid tick Amblyomma ameήcanum EcR ("AmaEcR"). Even more preferably, the LBD is from spruce budworm (Choristoneurafumiferana) EcR ("CfEcR") or fruit fly Drosophila melanogaster EcR
("DmEcR").
Preferably, the LBD is from a trancated insect EcR. The insect EcR polypeptide truncation comprises a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 2^5, 240, 245,
250, 255, 260, or 265 amino acids. More preferably, the insect EcR polypeptide truncation comprises a deletion of at least a partial polypeptide domain. Even more preferably, the insect EcR polypeptide truncation comprises a deletion of at least an entire polypeptide domain. In a
specific embodiment, the insect EcR polypeptide truncation comprises a deletion of at least an A B-domain deletion, a C-domain deletion, a D-domain deletion, an E-domain deletion, an F- domain deletion, an A B/C-domains deletion, an A/B/l/2-C-domains deletion, an A/B/C/D- domains deletion, an A/B/C/D/F-domains deletion, an A/B/F-domains, and an A/B/C/F- domains deletion. A combination of several complete and/or partial domain deletions may also be performed.
In a preferred embodiment, the ecdysone receptor Ugand binding domain is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
In another preferred embodiment, the ecdysone receptor Ugand binding domain comprises a polypeptide sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20. Preferably, the RXR polypeptide is a mouse Mus musculus RXR ("MmRXR") or a human Homo sapiens RXR ("HsRXR"). The RXR polypeptide may be an RXRα, RXRp, or RXRγisoform.
Preferably, the LBD is from a trancated RXR. The RXR polypeptide truncation comprises a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, or 265 amino acids. More preferably, the RXR polypeptide truncation comprises a deletion of at least a partial polypeptide domain. Even more preferably, the RXR polypeptide truncation comprises a deletion of at least an entire polypeptide domain. In a specific embodiment, the RXR polypeptide truncation comprises a deletion of at least an A/B-domain deletion, a C-domain deletion, a D-domain deletion, an E-domain deletion, an F-domain deletion, an A/B/C-domains deletion, an A/B/l/2-C-domains deletion, an A B/C/D-domains deletion, an A/B/C D/F-domains deletion, an A/B/F-domains, and an A/B/C/F-domains deletion. A combination of several complete and/or partial domain deletions may also be performed. ^
In a preferred embodiment, the retinoid X receptor ligand binding domain is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ
ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
In another preferred embodiment, the retinoid X receptor Ugand binding domain comprises a polypeptide sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
For purposes of this invention EcR and RXR also include synthetic and chimeric EcR and RXR and their homologs.
The DNA binding domain can be any DNA binding domain with a known response element, including synthetic and chimeric DNA binding domains, or analogs, combinations, or modifications thereof. Preferably, the DBD is a GAL4 DBD, a LexA DBD, a transcription factor DBD, a steroid/thyroid hormone nuclear receptor superfamily member DBD, a bacterial LacZ DBD, or a yeast put DBD. More preferably, the DBD is a GAL4 DBD [SEQ ID NO: 41 (polynucleotide) or SEQ ID NO: 42 (polypeptide)] or a LexA DBD [(SEQ ID NO: 43 (polynucleotide) or SEQ ID NO: 44 (polypeptide)]. The transactivation domain (abbreviated "AD" or "TA") may be any steroid/thyroid hormone nuclear receptor AD, synthetic or chimeric AD, polyglutamine AD, basic or acidic amino acid AD, a VP16 AD, a GAL4 AD, an NF-κB AD, a BP64 AD, or an analog, combination, or modification thereof. Preferably, the AD is a synthetic or chimeric AD, or is obtained from a VP16, GAL4, or NF-kB. Most preferably, the AD is a VP16 AD [SEQ ID NO: 45 (polynucleotide) or SEQ ID NO: 46 (polypeptide)].
The response element ("RE") may be any response element with a known DNA binding domain, or an analog, combination, or modification thereof. Preferably, the RE is an RE from GAL4 ("GAL4RE"), LexA, a steroid/thyroid hormone nuclear receptor RE, or a synthetic RE that recognizes a synthetic DNA binding domain. More preferably, the RE is a GAL4RE comprising a polynucleotide sequence of SEQ ID NO: 47 or a LexA 8X operon comprising a polynucleotide sequence of SEQ ID NO: 48. Preferably, the first hybrid protein is substantiaUy free of a transactivation domain and the second hybrid protein is substantially free of a DNA binding domain. For purposes of this invention, "substantiaUy free" means that the protein in question does not contain a sufficient sequence of the domain in question to provide activation or binding activity.
The Ugands for use in the present invention as described below, when combined with the ligand binding domain of an EcR, USP, RXR, or another polypeptide which in turn are bound to the response element Unked to a gene, provide the means for external temporal
regulation of expression of the gene. The binding mechanism or the order in which the various components of this invention bind to each other, that is, ligand to receptor, first polypeptide to response element, second polypeptide to promoter, etc., is not critical. Bmding of the ligand to the ligand binding domains of an EcR, USP, RXR, or another protein, enables expression or suppression of the gene. This mechanism does not exclude the potential for Ugand binding to EcR, USP, or RXR, and the resulting formation of active homodimer complexes (e.g. EcR+EcR or USP+USP). Preferably, one or more of the receptor domains can be varied producing a chimeric gene switch. TypicaUy, one or more of the three domains, DBD, LBD, and transactivation domain, may be chosen from a source different than the source of the other domains so that the chimeric genes and the resulting hybrid proteins are optimized in the chosen host cell or organism for transactivating activity, complementary binding of the ligand, and recognition of a specific response element. In addition, the response element itself can be modified or substituted with response elements for other DNA binding protein domains such as the GAL-4 protein from yeast (see Sadowski, et al. (1988) Nature, 335:563-564) or LexA protein fromE. coli (see Brent and Ptashne (1985), CeU, 43:729-736), or synthetic response elements specific for targeted interactions with proteins designed, modified, and selected for such specific interactions (see, for example, Kim, et al. (1997), Proc. Natl. Acad. Sci., USA, 94:3616-3620) to accommodate chimeric receptors. Another advantage of chimeric systems is that they aUow choice of a promoter used to drive the gene expression according to a desired end result. Such double control can be particularly important in areas of gene therapy, especially when cytotoxic proteins are produced, because both the liming of expression as well as the ceUs wherein expression occurs can be contiroUed. When genes, operatively linked to a suitable promoter, are introduced into the ceUs of the subject, expression of the exogenous genes is contiroUed by the presence of the system of this invention. Promoters may be constitutively or inducibly regulated or may be tissue-specific (that is, expressed only in a particular type of ceUs) or specific to certain developmental stages of the organism.
GENE EXPRESSION CASSETTES OF THE INVENTION
The novel ecdysone receptor-based inducible gene expression system of the invention comprises a novel gene expression cassette that is capable of being expressed n a host ceU, wherein the gene expression cassette comprises a polynucleotide encoding a hybrid polypeptide. Thus, Applicants' invention also provides novel gene expression cassettes for use in the gene expression system of the invention.
SpecificaUy, the present invention provides a gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide. The hybrid polypeptide comprises either 1) a DNA-binding domain that recognizes a response element and a Ugand binding domain of a nuclear receptor or 2) a transactivation domain and a ligand binding domain of a nuclear 5 receptor, wherein the transactivation domain is from a nuclear receptor other than an EcR, an RXR, or a USP.
In a specific embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a DNA-binding domain that recognizes a response element and an ecdysone receptor Ugand binding domain, wherein the DNA binding domain is from a nuclear receptor 10 other than an ecdysone receptor.
In another specific embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a DNA-binding domain that recognizes a response element and a retinoid X receptor Ugand binding domain, wherein the DNA binding domain is from a nuclear receptor other than a retinoid X receptor. 15 The DNA binding domain can be any DNA binding domain with a known response element, including synthetic and chimeric DNA binding domains, or analogs, combinations, or modifications thereof. Preferably, the DBD is a GAL4 DBD, a LexA DBD, a transcription factor DBD, a steroid/thyroid hormone nuclear receptor superfamily member DBD, a bacterial LacZ DBD, or a yeast put DBD. More preferably, the DBD is a GAL4 DBD [SEQ ID NO: 20 41 (polynucleotide) or SEQ ID NO: 42 (polypeptide)] or a LexA DBD [(SEQ ID NO: 43 (polynucleotide) or SEQ ID NO: 44 (polypeptide)].
In another specific embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a transactivation domain and an ecdysone receptor Ugand binding domain, wherein the transactivation domain is from a nuclear receptor other than an ecdysone
25 receptor.
In another specific embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a transactivation domain and a retinoid X receptor Ugand binding domain, wherein the transactivation domain is from a nuclear receptor other than a retinoid X receptor.
30 The transactivation domain (abbreviated "AD" or "TA") may be any steroid/thyroid hormone nuclear receptor AD, synthetic or chimeric AD, polyglutamine AD, basic or acidic amino acid AD, a VP16 AD, a GAL4 AD, an NF-κB AD, a BP64 AD, or an analog, combination, or modification thereof. Preferably, the AD is a synthetic or chimeric AD, or is
obtained from a VP16, GAL4, or NF-kB. Most preferably, the AD is a VP16 AD [SEQ ID NO: 45 (polynucleotide) or SEQ ID NO: 46 (polypeptide)].
Preferably, the Ugand binding domain is an EcR or RXR related steroid/thyroid hormone nuclear receptor family member ligand bmding domain, or analogs, combinations, or modifications thereof. More preferably, the LBD is from EcR or RXR. Even more preferably, the LBD is from a truncated EcR or RXR.
Preferably, the EcR is an insect EcR selected from the group consisting of a Lepidopteran EcR, a Dipteran EcR, an Arthropod EcR, a Homopteran EcR and a Hemipteran EcR. More preferably, the EcR for use is a spruce budworm Choristoneurafumiferana EcR ("CfEcR"), a Tenebrio molitor EcR ("TmEcR"), a Manduca sexta EcR ("MsEcR"), a
Heliothies virescens EcR ("HvEcR"), a sUk moth Bombyx mori EcR ("BmEcR"), a fruit fly Drosophila melanogaster EcR ("DmEcR"), a mosquito Aedes aegypti EcR ("AaEcR"), a blowfly LuciUa capitata EcR ("LcEcR"), a Mediterranean fruit fly Ceratitis capitata EcR ("CcEcR"), a locust Locusta migratoria EcR ("LmEcR"), an aphid Myzus persicae EcR ("MpEcR"), a fiddler crab Uca pugilator EcR ("UpEcR"), or an ixodid tick A mblyomma americanum EcR ("AmaEcR"). Even more preferably, the LBD is from spruce budworm (Choristoneurafumiferana) EcR ("CfEcR") or fruit fly Drosophila melanogaster EcR ("DmEcR").
Preferably, the LBD is from a truncated insect EcR. The insect EcR polypeptide truncation comprises a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, or 265 amino acids. More preferably, the insect EcR polypeptide truncation comprises a deletion of at least a partial polypeptide domain. Even more preferably, the insect EcR polypeptide truncation comprises a deletion of at least an entire polypeptide domain. In a specific embodiment, the insect EcR polypeptide truncation comprises a deletion of at least an A/B-domain deletion, a C-domain deletion, a D-domain deletion, an E-domain deletion, an F- domain deletion, an A B/C-domains deletion, anA/B/l/2-C-domains deletion, an A/B/C/D- domains deletion, an A/B/C/D/F-domains deletion, an A/B/F-domains, and an A B/C/F- domains deletion. A combination of several complete and/or partial domain deletions may also be performed.
In a prefened embodiment, the ecdysone receptor Ugand binding domain is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ
ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
In another preferred embodiment, the ecdysone receptor Ugand binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
Preferably, the RXR polypeptide is a mouse Mus musculus RXR ("MmRXR") or a human Homo sapiens RXR ("HsRXR"). The RXR polypeptide may be an RXRα, RXRβ, or RXRyisoform. Preferably, the LBD is from a trancated RXR. The RXR polypeptide truncation comprises a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, or 265 amino acids. More preferably, the RXR polypeptide truncation comprises a deletion of at least a partial polypeptide domain. Even more preferably, the RXR polypeptide truncation comprises a deletion of at least an entire polypeptide domain. In a specific embodiment, the RXR polypeptide truncation comprises a deletion of at least an A/B-domain deletion, a C-domain deletion, a D-domain deletion, an E-domain deletion, an F-domain deletion, an A B/C-domains deletion, an A/B/l/2-C-domains deletion, an A/B/C/D-domains deletion, an A/B/C D/F-domains deletion, an A/B/F-domains, and an A/B/C/F-domains deletion. A combination of several complete and/or partial domain deletions may also be performed.
In a preferred embodiment, the retinoid X receptor ligand binding domain is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
In another preferred embodiment, the retinoid X receptor Ugand binding domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
In a prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a DNA-binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 41) or a LexA
DBD (SEQ ID NO: 43) and an ecdysone receptor Ugand binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. In another prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a DNA-binding domain comprising a polypeptide sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 42) or a LexA DBD (SEQ ID NO: 44) and an ecdysone receptor ligand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
In another prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a DNA-binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 41) or a LexA DBD (SEQ ID NO: 43) and a retinoid X receptor ligand binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
In another prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a DNA-binding domain comprising a polypeptide sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 42) or a LexA DBD (SEQ ID NO: 44) and a retinoid X receptor Ugand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
In another prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a transactivation domain encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO: 45 and an ecdysone receptor ligand binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 SEQ ID NO: 5,
SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. In another prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a transactivation domain comprising a polypeptide sequence of SEQ
ID NO: 46 and an ecdysone receptor ligand binding domain comprising a polypeptide sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20. In another prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a transactivation domain encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO: 45 and a retinoid X receptor ligand binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
In another prefened embodiment, the gene expression cassette encodes a hybrid polypeptide comprising a transactivation domain comprising a polypeptide sequence of SEQ ID NO: 46 and a retinoid X receptor Ugand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
For purposes of this invention EcR and RXR also include synthetic and chimeric EcR and RXR and their homologs.
POLYNUCLEOTIDES OF THE INVENTION
The novel ecdysone receptor-based inducible gene expression system of the invention comprises a gene expression cassette comprising a polynucleotide that encodes a trancated EcR or RXR polypeptide comprising a truncation mutation and is useful in methods of modulating the expression of a gene within a host cell.
Thus, the present invention also relates to a polynucleotide that encodes an EcR or RXR polypeptide comprising a truncation mutation. Specifically, the present invention relates to an isolated polynucleotide encoding an EcR or RXR polypeptide comprising a truncation mutation that affects ligand binding activity or Ugand sensitivity. Preferably, the truncation mutation results in a polynucleotide that encodes a trancated
EcR polypeptide or a truncated RXR polypeptide comprising a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210,
215, 220, 225, 230, 235, 240, 245, 250, 255, 260, or 265 amino acids. More preferably, the EcR or RXR polypeptide truncation comprises a deletion of at least a partial polypeptide domain. Even more preferably, the EcR or RXR polypeptide truncation comprises a deletion of at least an entire polypeptide domain. In a specific embodiment, the EcR or RXR polypeptide truncation comprises a deletion of at least an A/B-domain deletion, a C-domain deletion, a D-domain deletion, an E-domain deletion, an F-domain deletion, an A/B/C-domains deletion, an A/B/l/2-C-domair_s deletion, an A B/C D-domains deletion, an A/B/C/D/F- domains deletion, an A/B/F-domains, and an A/B/C/F-domains deletion. A combination of several complete and/or partial domain deletions may also be performed. In a specific embodiment, the EcR polynucleotide according to the invention comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10. In a specific embodiment, the polynucleotide according to the invention encodes a ecdysone receptor polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11 (CfEcR-CDEF), SEQ ID NO: 12 (CfEcR- 1/2CDEF, which comprises the last 33 carboxy-terminal amino acids of C domain), SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 15 (CfEcR-DE ), SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17 (DmEcR- 1/2CDEF), SEQ ID NO: 18 (DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF), and SEQ ID NO: 20 (DmEcR- DE).
In another specific embodiment, the RXR polynucleotide according to the invention comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30. In another specific embodiment, the polynucleotide according to the invention encodes a truncated RXR polypeptide comprising an amino acid sequence consisting of SEQ ID NO: 31 (MmRXR- CDEF), SEQ ID NO: 32 (MmRXR-DEF), SEQ ID NO: 33 (M RXR-EF), SEQ ID NO: 34 (MmRXR-truncatedEF), SEQ ID NO: 35 (MmRXR-E), SEQ ID NO: 36 (HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ ID NO: 38 (HsRXR-EF), SEQ ID NO: 39 (HsRXR- trancated EF), and SEQ ID NO: 40 (HsRXR-E).
In particular, the present invention relates to an isolated polynucleotide encoding an EcR or RXR polypeptide comprising a truncation mutation, wherein the mutation reduces ligand binding activity or Ugand sensitivity of the EcR or RXR polypeptide. In a specific
embodiment, the present invention relates to an isolated polynucleotide encoding an EcR or RXR polypeptide comprising a truncation mutation that reduces steroid binding activity or steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated polynucleotide encoding an EcR polypeptide comprising a truncation mutation that reduces steroid binding activity or steroid sensitivity of the EcR polypeptide, wherein the polynucleotide comprises a nucleic acid sequence of SEQ ID NO: 3 (CfEcR-DEF), SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 8 (DmEcR-DEF), or SEQ ID NO: 9 (DmEcR-EF). In another specific embodiment, the present invention relates to an isolated polynucleotide encoding an EcR or RXR polypeptide comprising a truncation mutation that reduces non-steroid binding activity or non-steroid sensitivity of the EcR or RXR polypeptide. In a preferred embodiment, the present invention relates to an isolated polynucleotide encoding an EcR polypeptide comprising a truncation mutation that reduces non-steroid binding activity or non-steroid sensitivity of the EcR polypeptide, wherein the polynucleotide comprises a nucleic acid sequence of SEQ ID NO: 4 (CfEcR-EF) or SEQ ID NO: 9 (DmEcR-EF). The present invention also relates to an isolated polynucleotide encoding an EcR or
RXR polypeptide comprising a truncation mutation, wherein the mutation enhances ligand binding activity or Ugand sensitivity of the EcR or RXR polypeptide. In a specific embodiment, the present invention relates to an isolated polynucleotide encoding an EcR or RXR polypeptide comprising a truncation mutation that enhances steroid bmding activity or steroid sensitivity of the EcR or RXR polypeptide. In another specific embodiment, the present invention relates to an isolated polynucleotide encoding an EcR or RXR polypeptide comprising a truncation mutation that enhances non-steroid binding activity or non-steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated polynucleotide encoding an EcR polypeptide comprising a truncation mutation that enhances non-steroid binding activity or non-steroid sensitivity of the EcR polypeptide, wherein the polynucleotide comprises a nucleic acid sequence of SEQ ID NO: 3 (CfEcR-DEF) or SEQ ID NO: 8 (DmEcR-DEF).
The present invention also relates to an isolated polynucleotide encoding a retinoid X receptor polypeptide comprising a truncation mutation that increases Ugand sensitivity of a heterodimer comprising the mutated retinoid X receptor polypeptide and a dimerization partner.
Preferably, the isolated polynucleotide encoding a retinoid X receptor polypeptide comprising a truncation mutation that increases Ugand sensitivity of a heterodimer comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO: 23 (MmRXR-EF),
SEQ ID NO: 24 (MmRXR-truncatedEF , SEQ ID NO: 28 (HsRXR-EF), or SEQ ID NO: 29 (HsRXR-truncated EF). In a specific embodiment, the dimerization partner is an ecdysone receptor polypeptide. Preferably, the dimerization partner is a truncated EcR polypeptide. More preferably, the dimerization partner is an EcR polypeptide in which domains A/B/C have 5 been deleted. Even more preferably, the dimerization partner is an EcR polypeptide comprising an amino acid sequence of SEQ ID NO: 13 (CfEcR-DEF) or SEQ ID NO: 18 (DmEcR-DEF).
POLYPEPTIDES OF THE INVENTION
The novel ecdysone receptor-based inducible gene expression system of the invention
10 comprises a polynucleotide that encodes a truncated EcR or RXR polypeptide and is useful in methods of modulating the expression of a gene within a host cell. Thus, the present invention also relates to an isolated truncated EcR or RXR polypeptide encoded by a polynucleotide or a gene expression cassette according to the invention. SpecificaUy, the present invention relates to an isolated truncated EcR or RXR polypeptide comprising a truncation mutation that affects
15 ligand binding activity or Ugand sensitivity encoded by a polynucleotide according to the invention.
The present invention also relates to an isolated truncated EcR or RXR polypeptide comprising a truncation mutation. Specifically, the present invention relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that affects Ugand binding activity or
20 ligand sensitivity.
Preferably, the truncation mutation results in a trancated EcR polypeptide or a truncated RXR polypeptide comprising a deletion of at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225,
25 230, 235, 240, 245, 250, 255, 260, or 265 amino acids. More preferably, the EcR or RXR polypeptide truncation comprises a deletion of at least a partial polypeptide domain. Even more preferably, the EcR or RXR polypeptide truncation comprises a deletion of at least an entire polypeptide domain. In a specific embodiment, the EcR or RXR polypeptide truncation comprises a deletion of at least an A/B-domain deletion, a C-domain deletion, a D-domain
30 deletion, an E-domain deletion, an F-domain deletion, an A B/C-domains deletion, an A/B/l/2-
C-domains deletion, an A/B/C/D-domains deletion, an A/B/C/D/F-domains deletion, an A/B/F- domains, and an A/B/C/F-domains deletion. A combination of several complete and/or partial domain deletions may also be performed.
In a prefened embodiment, the isolated trancated ecdysone receptor polypeptide is encoded by a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1 (CfEcR-CDEF), SEQ ID NO: 2 (CfEcR- 1/2CDEF), SEQ ID NO: 3 (CfEcR-DEF), SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 5 (CfEcR-DE), SEQ ID NO: 6 (DmEcR-CDEF), SEQ ID NO: 7 (DmEcR- 1/2CDEF), SEQ ID NO: 8 (DmEcR-DEF), SEQ ID NO: 9 (DmEcR-EF), and SEQ ID NO: 10 (DmEcR-DE). In another prefened embodiment, the isolated truncated ecdysone receptor polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 (CfEcR-CDEF), SEQ ID NO: 12 (CfEcR-l/2CDEF), SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 15 (CfEcR-DE), SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17 (DmEcR-l/2CDEF), SEQ ID NO: 18 (DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF), and SEQ ID NO: 20 (DmEcR-DE).
In a prefened embodiment, the isolated trancated RXR polypeptide is encoded by a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 21 (MmRXR-CDEF), SEQ ID NO: 22 (MmRXR-DEF), SEQ ID NO: 23
(MmRXR-EF), SEQ ID NO: 24 (MmRXR-trancatedEF), SEQ ID NO: 25 (MmRXR-E), SEQ ID NO: 26 (HsRXR-CDEF), SEQ ID NO: 27 (HsRXR-DEF), SEQ ID NO: 28 (HsRXR-EF), SEQ ID NO: 29 (HsRXR-truncatedEF) and SEQ ID NO: 30 (HsRXR-E). In another prefened embodiment, the isolated trancated RXR polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31 (MmRXR-CDEF), SEQ ID NO: 32 (MmRXR-DEF), SEQ ID NO: 33 (MmRXR-EF), SEQ ID NO: 34 (MmRXR- trancatedEF), SEQ ID NO: 35 (MmRXR-E), SEQ ID NO: 36 (HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ ID NO: 38 (HsRXR-EF), SEQ ID NO: 39 (HsRXR-truncatedEF), and SEQ ID NO: 40 (HsRXR-E). The present invention relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that reduces Ugand binding activity or Ugand sensitivity of the EcR or RXR polypeptide, wherein the polypeptide is encoded by a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1 (CfEcR-CDEF), SEQ ID NO: 2 (CfEcR- 1/2CDEF), SEQ ID NO: 3 (CfEcR-DEF), SEQ ID NO: 4 (CfEcR- EF), SEQ ID NO: 5 (CfEcR-DE), SEQ ID NO: 6 (DmEcR-CDEF), SEQ ID $0: 7 (DmEcR-
1/2CDEF), SEQ ID NO: 8 (DmEcR-DEF), SEQ ID NO: 9 (DmEcR-EF), SEQ ID NO: 10 (DmEcR-DE), SEQ ID NO: 21 (MmRXR-CDEF), SEQ ID NO: 22 (MmRXR-DEF), SEQ ID NO: 23 (MmRXR-EF), SEQ ID NO: 24 (MmRXR-trancatedEF), SEQ ID NO: 25 (MmRXR-
E), SEQ ID NO: 26 (HsRXR-CDEF), SEQ ID NO: 27 (HsRXR-DEF), SEQ ID NO: 28 (HsRXR-EF), SEQ ID NO: 29 (HsRXR-truncatedEF), and SEQ ID NO: 30 (HsRXR-E).
Thus, the present invention relates to an isolated trancated EcR or RXR polypeptide comprising a truncation mutation that reduces Ugand binding activity or ligand sensitivity of the EcR or RXR polypeptide, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 (CfEcR-CDEF), SEQ ID NO: 12 (CfEcR-l/2CDEF), SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 15 (CfEcR-DE), SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17 (DmEcR- 1/2CDEF), SEQ ID NO: 18 (DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF), SEQ ID NO: 20 (DmEcR- DE), SEQ ID NO: 31 (MmRXR-CDEF), SEQ ID NO: 32 (MmRXR-DEF), SEQ ID NO: 33 (MmRXR-EF), SEQ ID NO: 34 (MmRXR-trancatedEF), SEQ ID NO: 35 (MmRXR-E), SEQ ID NO: 36 (HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ ID NO: 38 (HsRXR-EF), SEQ ID NO: 39 (HsRXR-truncatedEF), and SEQ ID NO: 40 (HsRXR-E).
In a specific embodiment, the present invention relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that reduces steroid binding activity or steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated EcR polypeptide comprising a truncation mutation that reduces steroid binding activity or steroid sensitivity of the EcR polypeptide, wherein the EcR polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO: 3 (CfEcR- DEF), SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 8 (DmEcR-DEF), or SEQ ID NO: 9
(DmEcR-EF). Accordingly, the present invention also relates to an isolated truncated EcR or RXR polypeptide comprising a truncation mutation that reduces steroid binding activity or steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated EcR polypeptide comprising a truncation mutation that reduces steroid binding activity or steroid sensitivity of the EcR polypeptide, wherein the EcR polypeptide comprises an amino acid sequence of SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 18 (DmEcR-DEF), or SEQ ID NO: 19 (DmEcR-EF).
In another specific embodiment, the present invention relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that reduces non-steroid binding activity or non-steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated EcR polypeptide comprising a truncation mutation that reduces non-steroid binding activity or non-steroid sensitivity of the EcR polypeptide, wherein the EcR polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO:
4 (CfEcR-EF) or SEQ ID NO: 9 (DmEcR-EF). Accordingly, the present invention also relates to an isolated trancated EcR or RXR polypeptide comprising a trancation mutation that reduces non-steroid binding activity or steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated EcR polypeptide comprising a trancation mutation that reduces non-steroid binding activity or non-steroid sensitivity of the EcR polypeptide, wherein the EcR polypeptide comprises an amino acid sequence of SEQ ID NO: 14 (CfEcR-EF) or SEQ ID NO: 19 (DmEcR-EF).
In particular, the present invention relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that enhances Ugand binding activity or ligand sensitivity of the EcR or RXR polypeptide, wherein the polypeptide is encoded by a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1 (CfEcR-CDEF), SEQ ID NO: 2 (CfEcR- 1/2CDEF), SEQ ID NO: 3 (CfEcR-DEF), SEQ ID NO: 4 (CfEcR-EF), SEQ ID NO: 5 (CfEcR-DE), SEQ ID NO: 6 (DmEcR-CDEF), SEQ ID NO: 7 (DmEcR- 1/2CDEF), SEQ ID NO: 8 (DmEcR-DEF), SEQ ID NO: 9 (DmEcR-EF), SEQ ID NO: 10 (DmEcR-DE), SEQ ID NO: 21 (MmRXR-CDEF), SEQ ID NO: 22
(MmRXR-DEF), SEQ ID NO: 23 (MmRXR-EF), SEQ ID NO: 24 (MmRXR-trancatedEF), SEQ ID NO: 25 (MmRXR-E), SEQ ID NO: 26 (HsRXR-CDEF), SEQ ID NO: 27 (HsRXR- DEF), SEQ ID NO: 28 (HsRXR-EF), SEQ ID NO: 29 (HsRXR-trancated EF), and SEQ ID NO: 30 (HsRXR-E). The present invention relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that enhances ligand binding activity or Ugand sensitivity of the EcR or RXR polypeptide, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11 (CfEcR-CDEF), SEQ ID NO: 12 (CfEcR- 1/2CDEF), SEQ ID NO: 13 (CfEcR-DEF), SEQ ID NO: 14 (CfEcR-EF), SEQ ID NO: 15 (CfEcR-DE), SEQ ID NO: 16 (DmEcR-CDEF), SEQ ID NO: 17 (DmEcR- 1 2CDEF), SEQ ID NO: 18 (DmEcR-DEF), SEQ ID NO: 19 (DmEcR-EF), SEQ ID NO: 20 (DmEcR-DE), SEQ ID NO: 31 (MmRXR-CDEF), SEQ ID NO: 32 (MmRXR-DEF), SEQ ID NO: 33 (MmRXR-EF), SEQ ID NO: 34 (MmRXR-trancatedEF), SEQ ID NO: 35 (MmRXR-E), SEQ ID NO: 36 (HsRXR-CDEF), SEQ ID NO: 37 (HsRXR-DEF), SEQ ID NO: 39 (HsRXR-EF), SEQ ID NO: 39 (HsRXR-truncatedEF), and SEQ ID NO: 40 (HsRXR-E).
The present invention relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that enhances ligand binding activity or Ugand sensitivity of the EcR or RXR polypeptide. In a specific embodiment, the present invention relates to an isolated EcR or
RXR polypeptide comprising a truncation mutation that enhances steroid binding activity or steroid sensitivity of the EcR or RXR polypeptide. Accordingly, the present invention also relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that enhances steroid binding activity or steroid sensitivity of the EcR or RXR polypeptide. In another specific embodiment, the present invention relates to an isolated EcR or
RXR polypeptide comprising a truncation mutation that enhances non-steroid binding activity or non-steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated EcR polypeptide comprising a truncation mutation that enhances non-steroid binding activity or non-steroid sensitivity of the EcR polypeptide, wherein the EcR polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO: 3 (CfEcR-DEF) or SEQ ID NO: 8 (DmEcR-DEF). Accordingly, the present invention also relates to an isolated EcR or RXR polypeptide comprising a truncation mutation that enhances non-steroid binding activity or steroid sensitivity of the EcR or RXR polypeptide. In a prefened embodiment, the present invention relates to an isolated EcR polypeptide comprising a truncation mutation that enhances non-steroid binding activity or non-steroid sensitivity of the EcR polypeptide, wherein the EcR polynucleotide comprises an amino acid sequence of SEQ ID NO: 13 (CfEcR-DEF) or SEQ ID NO: 18 (DmEcR-DEF).
The present invention also relates to an isolated retinoid X receptor polypeptide comprising a truncation mutation that increases Ugand sensitivity of a heterodimer comprising the mutated retinoid X receptor polypeptide and a dimerization partner. Preferably, the isolated retinoid X receptor polypeptide comprising a trancation mutation that increases ligand sensitivity of a heterodimer is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 23 (MmRXR-EF), SEQ ID NO: 24 (MmRXR-trancatedEF), SEQ ID NO: 28 (HsRXR-EF), or SEQ ID NO: 29 (HsRXR- trancatedEF). More preferably, the isolated polynucleotide encoding a retinoid X receptor polypeptide comprising a truncation mutation that increases ligand sensitivity of a heterodimer comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 33 (MmRXR-EF), SEQ ID NO: 34 (MmRXR-trancatedEF), SEQ ID NO: 38 (HsRXR-EF), or SEQ ID NO: 39 (HsRXR-truncatedEF). In a specific embodiment, the dimerization partner is an ecdysone receptor polypeptide.
Preferably, the dimerization partner is a truncated EcR polypeptide. More preferably, the dimerization partner is an EcR polypeptide in which domains A/B/C have been deleted. Even more preferably, the dimerization partner is an EcR polypeptide comprising an amino acid
sequence of SEQ ID NO: 13 (CfEcR-DEF) or SEQ ID NO: 18 (DmEcR-DEF).
METHOD OF MODULATING GENE EXPRESSION OF THE INVENTION
Applicants' invention also relates to methods of modulating gene expression in a host cell using a gene expression modulation system according to the invention. SpecificaUy, Applicants' invention provides a method of modulating the expression of a gene in a host cell comprising the steps of: a) introducing into the host cell a gene expression modulation system according to the invention; and b) introducing into the host cell a ligand that independently combines with the Ugand binding domains of the first polypeptide and the second polypeptide of the gene expression modulation system; wherein the gene to be expressed is a component of a gene expression cassette comprising: i) a response element comprising a domain to which the DNA binding domain of the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and Ui) a gene whose expression is to be modulated, whereby a complex is formed comprising the Ugand, the first polypeptide of the gene expression modulation system and the second polypeptide of the gene expression modulation system, and whereby the complex modulates expression of the gene in the host cell.
Genes of interest for expression in a host ceU using Applicants' methods may be endogenous genes or heterologous genes. Nucleic acid or amino acid sequence information for a desired gene or protein can be located in one of many pubUc access databases, for example, GENB ANK, EMBL, Swiss-Prot, and PIR, or in many biology related journal pubUcations. Thus, those skilled in the art have access to nucleic acid sequence information for virtually all known genes. Such information can then be used to construct the desired constructs for the insertion of the gene of interest within the gene expression cassettes used in AppUcants' methods described herein. Examples of genes of interest for expression in a host ceU using AppUcants' methods include, but are not Umited to: antigens produced in plants as vaccines, enzymes Uke alpha- amylase, phytase, glucanes, and xylanse, genes for resistance against insects, nematodes, fungi, bacteria, viruses, and abiotic stresses, nutraceuticals, pharmaceuticals, vitamins, genes for modifying amino acid content, herbicide resistance, cold, drought, and heat tolerance, industrial products, oils, protein, carbohydrates, antioxidants, male sterile plants, flowers, fuels, other output traits, genes encoding therapeuticaUy desirable polypeptides or products, such as genes that can provide, modulate, alleviate, conect and/or restore polypeptides important in treating a condition, a disease, a disorder, a dysfunction, a genetic defect, and the Uke.
Acceptable Ugands are any that modulate expression of the gene when binding of the DNA binding domain of the two hybrid system to the response element in the presence of the ligand results in activation or suppression of expression of the genes. Prefened Ugands include ponasterone, muristerone A, N,N'-diacylhydrazines such as those disclosed inU. S. Patents No. 6,013,836; 5,117,057; 5,530,028; and 5,378,726; dibenzoylalkyl cyanohydrazines such as those disclosed in European AppUcation No. 461,809; N-alkyl-N,N'-diaroylhydrazines such as those disclosed in U. S. Patent No. 5,225,443; N-acyl-N-alkylcarbonylhydrazines such as those disclosed in European AppUcation No. 234,994; N-aroyl-N-alkyl-N'-aroylhydrazines such as those described in U. S. Patent No. 4,985,461 ; each of which is incorporated herein by reference and other similar materials including 3 ,5-di-tert-butyl-4-hydroxy-N-isobutyl- benzamide, 8-O-acetylharpagide, and the like.
Preferably, the Ugand for use in AppUcants' method of modulating expression of gene is a compound of the formula:
wherein:
E is a (C4-Ce)alkyl containing a tertiary carbon or a cyano(C3-Cs)alkyl containing a tertiary carbon;
R1 is H, Me, Et, i-Pr, F, for yl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-propynyl, 2-proρynyl, vinyl, OH, OMe, OEt, cyclopropyl, CF2CF3, CH=CHCN, allyl, azido, SCN, or SCHF2;
R2 is H, Me, Et, n-Pr, i-Pr, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, Ac, F, CI, OH, OMe, OEt, O-n- Pr, OAc, NMez, NEt2, SMe, SEt, SOCF3, OCF2CF2H, COEt, cyclopropyl, CF2CF3, CH=CHCN, allyl, azido, OCF3) OCHF2, O-i-Pr, SCN, SCHF2, SOMe, NH-CN, or joined with R3 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon;
R3 is H, Et, or joined with R2 and the phenyl carbons to which R2 and R3 are attached to
form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon; R4, Rs, and R6 are independently H, Me, Et, F, CI, Br, formyl, CF3, CHF2, CHC12, CH2F, CH2CI, CH2OH, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or SEt. Applicants' mvention provides for modulation of gene expression in prokaryotic and eukaryotic host cells. Thus, the present invention also relates to a method for modulating gene expression in a host ceU selected from the group consisting of a bacterial ceU, a fungal ceU, a yeast cell, a plant cell, an animal cell, and a mammaUan cell. Preferably, the host cell is a yeast cell, a plant ceU, a murine ceU, or a human cell. Expression in transgenic host ceUs may be useful for the expression of various polypeptides of interest including but not limited to therapeutic polypeptides, pathway intermediates; for the modulation of pathways already existing in the host for the synthesis of new products heretofore not possible using the host; cell based assays; and the like. Additionally the gene products may be useful for conferring higher growth yields of the host or for enabling alternative growth mode to bs utilized.
HOST CELLS AND NON-HUMAN ORGANISMS OF THE INVENTION
As described above, the gene expression modulation system of the present invention may be used to modulate gene expression in a host cell. Expression in transgenic host cells may be useful for the expression of various genes of interest. Thus, AppUcants' invention also provides an isolated host cell comprising a gene expression system according to the invention. The present invention also provides an isolated host ceU comprising a gene expression cassette according to the invention. AppUcants' invention also provides an isolated host cell comprising a polynucleotide or polypeptide according to the invention. The isolated host cell may be either a prokaryotic or a eukaryotic host ceU.
Preferably, the host ceU is selected from the group consisting of a bacterial ceU, a fungal ceU, a yeast cell, a plant cell, an animal cell, and a mammaUan cell. Examples of preferred host ceUs include, but are not Umited to, fungal or yeast species such as Aspergillus, Tήchoderma, Saccharomyces, Pichia, Candida, Hansenula, or bacterial species such as those in the genera Synechocystis, Synechococcus, Salmonella, Bacillus, Acinetobacter,
Rhodococcus, Streptomyces, Escherichia, Pseudomonas, Methylomonas, Methylobacter, Alcaligenes, Synechocystis, Anabaena, Thiobacillus, Methanobacterium and Klebsieϊla, plant, animal, and mammaUan host ceUs. More preferably, the host cell is a yeast ceU, a plant
ceU, a murine ceU, or a human cell.
In a specific embodiment, the host ceU is a yeast ceU selected from the group consisting of a Saccliaromyces, a Pichia, and a Candida host cell.
In another specific embodiment, the host cell is a plant ceU selected from the group consisting of an apple, Arabidopsis, bajra, banana, barley, bean, beet, blackgram, chickpea, chiU, cucumber, eggplant, favabean, maize, melon, millet, mungbean, oat, okra, Panicum, papaya, peanut, pea, pepper, pigeonpea, pineapple, Phaseolus, potato, pumpkin, rice, sorghum, soybean, squash, sugarcane, sugarbeet, sunflower, sweet potato, tea, tomato, tobacco, watermelon, and wheat host cell. In another specific embodiment, the host cell is a murine ceU.
In another specific embodiment, the host cell is a human cell.
Host cell transformation is weU known in the art and may be achieved by a variety of methods including but not limited to electroporation, viral infection, plasmid vector transfection, non-viral vector mediated transfection, Agrobacterium-meάiateά transformation, particle bombardment, and the like. Expression of desired gene products involves culturing the transformed host cells under suitable conditions and inducing expression of the transformed gene. Culture conditions and gene expression protocols in prokaryotic and eukaryotic cells are well known in the art (see General Methods section of Examples). CeUs may be harvested and the gene products isolated according to protocols specific for the gene product. In addition, a host cell may be chosen which modulates the expression of the inserted polynucleotide, or modifies and processes the polypeptide product in the specific fashion desired. Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage [e.g., of signal sequence]) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce a non-glycosylated core protein product. However, a polypeptide expressed in bacteria may not be properly folded. Expression in yeast can produce a glycosylated product. Expression in eukaryotic ceUs can increase the likelihood of "native" glycosylation and folding of a heterologous protein. Moreover, expression in mammaUan cells can provide a tool for reconstituting, or constituting, the poljjpeptide's activity. Furthermore, different vector/host expression systems may affect processmg reactions, such as proteolytic cleavages, to a different extent.
Applicants' invention also relates to a non-human organism comprising an isolated host cell according to the invention. Preferably, the non-human organism is selected from the group consisting of a bacterium, a fungus, a yeast, a plant, an animal, and a mammal. More preferably, the non-human organism is a yeast, a plant, a mouse, a rat, a rabbit, a cat, a dog, a bovine, a goat, a pig, a horse, a sheep, a monkey, or a chimpanzee.
In a specific embodiment, the non-human organism is a yeast selected from the group consisting of Saccharomyces, Pichia, and Candida.
In another specific embodiment, the non-human organism is a plant selected from the group consisting of an apple, Arabidopsis, bajra, banana, barley, beans, beet, blackgram, chickpea, chiU, cucumber, eggplant, favabean, maize, melon, miUet, mungbean, oat, okra, Panicum, papaya, peanut, pea, pepper, pigeonpea, pineapple, Phaseolus, potato, pumpkin, rice, sorghum, soybean, squash, sugarcane, sugarbeet, sunflower, sweet potato, tea, tomato, tobacco, watermelon, and wheat.
In another specific embodiment, the non-human organism is a Mus musculus mouse.
MEASURING GENE EXPRESSION/TRANSCRIPTION
One useful measurement of AppUcants' methods of the invention is that of the transcriptional state of the ceU including the identities and abundances of RNA, preferably mRNA species. Such measurements are conveniently conducted by measuring cDNA abundances by any of several existing gene expression technologies.
Nucleic acid anay technology is a useful technique for determining differential mRNA expression. Such technology includes, for example, oUgonucleotide chips and DNA microanays. These techniques rely on DNA fragments or oUgonucleotides which conespond to different genes or cDNAs which are immobUized on a soUd support and hybridized to probes prepared from total mRNA pools extracted from cells, tissues, or whole organisms and converted to cDNA. OUgonucleotide chips are anays of oUgonucleotides synthesized on a substrate using photoUthographic techniques. Chips have been produced which can analyze for up to 1700 genes. DNA microanays are arrays of DNA samples, typicaUy PCR products, that are robotically printed onto a microscope sUde. Each gene is analyzed by a full or partial- length target DNA sequence. Microanays with up to 10,000 genes are now rqutinely prepared commerciaUy. The primary difference between these two techniques is that oUgonucleotide chips typically utiUze 25-mer oUgonucleotides which allow fractionation of short DNA molecules whereas the larger DNA targets of microanays, approximately 1000 base pairs, may
provide more sensitivity in fractionating complex DNA mixtures.
Another useful measurement of AppUcants' methods of the invention is that of deteirnining the translation state of the ceU by measuring the abundances of the constituent protein species present in the ceU using processes well known in the art. Where identification of genes associated with various physiological functions is desired, an assay may be employed in which changes in such functions as cell growth, apoptosis, senescence, differentiation, adhesion, binding to a specific molecules, binding to another cell, cellular organization, organogenesis, intracellular transport, transport facUitation, energy conversion, metaboUsm, myogenesis, neurogenesis, and/or hematopoiesis is measured. In addition, selectable marker or reporter gene expression may be used to measure gene expression modulation using AppUcants' invention.
Other methods to detect the products of gene expression are weU known in the art and include Southern blots (DNA detection), dot or slot blots (DNA, RNA), Northern blots (RNA), and RT-PCR (RNA) analyses. Although less prefened, labeled proteins can be used to detect a particular nucleic acid sequence to which it hybidizes.
In some cases it is necessary to ampUfy the amount of a nucleic acid sequence. This may be carried out using one or more of a number of suitable methods including, for example, polymerase chain reaction ("PCR"), Ugase chain reaction ("LCR"), strand displacement ampUfication ("SDA"), transcription-based ampUfication, and the Uke. PCR is carried out in accordance with known techniques in which, for example, a nucleic acid sample is treated in the presence of a heat stable DNA polymerase, under hybridizing conditions, with one oUgonucleotide primer for each strand of the specific sequence to be detected. An extension product of each primer that is synthesized is complementary to each of the two nucleic acid strands, with the primers sufficiently complementary to each strand of the specific sequence to hybridize therewith. The extension product synthesized from each primer can also serve as a template for further synthesis of extension products using the same primers. FoUowing a sufficient number of rounds of synthesis of extension products, the sample may be analyzed as described above to assess whether the sequence or sequences to be detected are present.
The present invention may be better understood by reference to the foljpwing non- limiting Examples, which are provided as exemplary of the invention.
EXAMPLES
GENERAL METHODS
Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, (1989) (Maniatis) and by T. J. Silhavy, M. L. Bennan, and L. W. Enquist, Experiments with Gene Fusions, Cold Spiring Harbor Laboratory, Cold Spring Harbor, N.Y. (1984) and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, Greene PubUshing Assoc. and WUey-Interscience (1987). Methods for plant tissue culture, transformation, plant molecular biology, and plant, general molecular biology may be found in Plant Tissue Culture Concepts and Laboratory Exercises edited by RN Trigiano and DJ Gray, 2nd edition, 2000, CRC press, New York; Agrobacterium Protocols edited by KMA Gartland and MR Davey, 1995, Humana Press, Totowa, New Jersey; Methods in Plant Molecular Biology, P. MaUga et al., 1995, Cold Spring Harbor Lab Press, New York; and Molecular Cloning, J. Sambrook et al., 1989, Cold Spring Harbor Lab Press, New York.
Materials and methods suitable for the maintenance and growth of bacterial cultures are well known in the art. Techniques suitable for use in the following examples may be found as set out in Manual of Methods for General Bacteriology (PhilUpp Gerhardt, R. G. E. Munay, Ralph N. Costilow, Eugene W. Nester, WiUis A. Wood, Noel R. Krieg and G. Briggs PhiUips, eds), American Society for Microbiology, Washington, DC. (1994)) or by Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, MA (1989). All reagents, restriction enzymes and materials used for the growth and maintenance of host ceUs were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or
Sigma Chemical Company (St. Louis, MO) unless otherwise specified.
Manipulations of genetic sequences may be accompUshed using the suite of programs available from the Genetics Computer Group Inc. (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI). Where the GCG program "Pileup" is used the gap creation default value of 12, and the gap extension default value of 4 may be used. Where the
CGC "Gap" or "Bestfit" programs is used the default gap creation penalty of 50 and the default gap extension penalty of 3 may be used. In any case where GCG program parameters are not prompted for, in these or any other GCG program, default values may be used.
The meaning of abbreviations is as follows: "h" means hour(s), "min" means minute(s), "sec" means second(s), "d" means day(s), "μl" means microUter(s), "ml" means milUUter(s), "L" means liter(s), "μM" means micromolar, "mM" means miUimolar, "μg" means microgram(s), "mg" means milUgram(s), "A" means adenine or adenosine, "T" means thymine or thymidine, "G" means guanine or guanosine, "C" means cytidine or cytosme, "x g" means times gravity, "nt" means nucleotide(s), "aa" means amino acid(s), "bp" means base pair(s), "kb" means kilobase(s), "k" means kilo, "μ" means micro, and "°C" means degrees Celsius.
EXAMPLE 1
AppUcants' improved EcR-based inducible gene modulation system was developed for use in various appUcations including gene therapy, expression of proteins of interest in host ceUs, production of transgenic organisms, and ceU-based assays. This Example describes the construction and evaluation of several gene expression cassettes for use in the EcR-based inducible gene expression system of the invention.
In various ceUular backgrounds, including mammaUan cells, insect ecdysone receptor (EcR) heterodimerizes with retinoid X receptor (RXR) and, upon binding of ligand, transactivates genes under the control of ecdysone response elements. AppUcants constructed several EcR-based gene expression cassettes based on the spruce budworm Choristoneura fumiferana EcR ("CfEcR"; fuU length polynucleotide and amino acid sequences are set forth in SEQ ID NO: 49 and SEQ ID NO: 50, respectively), C. fumiferana ultraspiracle ("CfUSP"; fuU length polynucleotide and amino acid sequences are set forth in SEQ ID NO: 51 and SEQ ID NO: 52, respectively), and mouse Mus musculus RXR (MmRXRα; full length polynucleotide and amino acid sequences are set forth in SEQ ID NO: 53 and SEQ ID NO: 54, respectively). The prepared receptor constracts comprise a Ugand binding domain of EcR and of RXR or of USP; a DNA binding domain of GAL4 or of EcR; and an activation domain of VP16. The reporter constructs include a reporter gene, luciferase or LacZ, operably linked to a synthetic promoter construct that comprises either GAL4 or EcR/USP binding sites (response elements). Various combinations of these receptor and reporter constructs were cotransfected into CHO, NIH3T3, CV1 and 293 ceUs. Gene induction potential (magnitude of induction) and ligand specificity and sensitivity were examined using four different Ugands: two steroidal Ugands (ponasterone A and muristerone A) and two non-steroidal Ugands (N-(2-ethyl-3-
memoxybenzoyl)-N'-(3,5-(_imethylbenzoyl)-N'-tert-butylhydrazine and N-(3,4-(l ,2- ethylene-Uoxy)-2-methylbenzoyl)-N'-(3,5-d_methylbenzoyl)-N'-tert-butylhydrazine) in a dose- dependent induction of reporter gene expression in the transfected ceUs. Reporter gene expression activities were assayed at 24hr or 48hr after ligand addition.
Gene Expression Cassettes: Ecdysone receptor-based, chemicaUy inducible gene expression cassettes (switches) were constructed as foUowed, using standard cloning methods available in the art. The following is brief description of preparation and composition of each switch.
1.1 - GAL4EcR/VP16RXR: The D, E, and F domains from spruce budworm Choristoneura fumiferana EcR ("CfEcRDEF"; SEQ ID NO: 3) were fused to GAL4 DNA binding domain
("DNABD"; SEQ ID NO: 41) and placed under the control of an SV40e promoter (SEQ ID NO: 55). The DEF domains from mouse (Mus musculus) RXR ("MmRXRDEF"; SEQ ID NO: 22) were fused to the activation domain from VP16 ("VP16AD"; SEQ ID NO: 45) and placed under the control of an SV40e promoter (SEQ ID NO: 55). Five consensus GAL4 binding sites ("5XGAL4RE"; comprising 5, GAL4RE comprising SEQ ID NO: 47) were fused to a synthetic Elb minimal promoter (SEQ ID NO: 56) and placed upstream of the luciferase gene (SEQ ID NO: 57).
1.2 - GAL4EcR/VP16USP: This construct was prepared in the same way as in switch 1.1 above except MmRXRDEF was replaced with the D, E and F domains from spruce budworm USP ("CfUSPDEF"; SEQ ID NO: 58). The constracts used in this example are simUar to those disclosed in U. S. Patent No. 5,880,333 except that Choristoneurafumiferana USP rather than Drosophila melanogaster USP was utilized.
1.3 - GAL4RXR/VP16CfEcR: MmRXRDEF (SEQ ID NO: 22) was fused to a GAL4DNABD (SEQ ID NO: 41) and CfEcRCDEF (SEQ ID NO: 1) was fused to a VP16AD (SEQ ID NO: 45).
1.4 - GAL4RXR/VP16DmEcR: This construct was prepared in the same way as switch 1.3 except CfEcRCDEF was replaced with DmEcRCDEF (SEQ ID NO: 6).
1.5 - GAL4USP/VP16CfEcR: This construct was prepared in the same way as switch 1.3 except MmRXRDEF was replaced with CfUSPDEF (SEQ ID NO: 58). 1.6 - GAL4RXRCfEcRVP16: This construct was prepared so that both the GAL4 DNABD and the VP16AD were placed on the same molecule. GAL4DNABD (SEQ ID NO: 41) and VP16AD (SEQ ID NO: 45) were fused to CfEcRDEF (SEQ ID NO: 3) at N-and C-termini respectively. The fusion was placed under the control of an S V40e promoter (SEQ ID NO:
55).
1.7 - VP16CfEcR: This construct was prepared such that CfEcRCDEF (SEQ ID NO: 1) was fused to VP16AD (SEQ ID NO: 45) and placed under the control of an SV40e promoter (SEQ ID NO: 55). Six ecdysone response elements ("EcRE"; SEQ ID NO: 59) from the hsp27 gene were placed upstream of the promoter and a luciferase gene (SEQ ID NO: 57). This switch most probably uses endogenous RXR.
1.8 - DmVgRXR: This system was purchased from Invitrogen Corp., Carlsbad, CaUfornia. It comprises a Drosophila melanogaster EcR ("DmEcR") with a modified DNABD fused to VP16AD and placed under the control of a CMV promoter (SEQ ID NO: 60). FuU length MmRXR (SEQ ID NO: 53) was placed under the control of the RSV promoter (SEQ ID NO: 61). The reporter, pIND(SPl)LacZ, contains five copies of a modified ecdysone response element ("EcRE", E/GRE), three copies of an SP1 enhancer, and a minimal heat shock promoter, aU of which were placed upstream to the LacZ reporter gene. .9 - CfVgRXR: This example was prepared in the same way as switch 1.8 except DmEcR was replaced with a truncated CfEcR comprising a partial A B domain and the complete CDEF domains [SEQ ID NO: 62 (polynucleotide) and SEQ ID NO: 63 (polypeptide)]. 1.10 - CfVgRXRdel: This example was prepared in the same way as switch 1.9 except MmRXR (SEQ ID NO: 53) was deleted.
Cell lines: Four ceU lines: CHO, Chinese hamster Cricetulus griseus ovarian ceU line;
NIH3T3 (3T3) mouse Mus musculus ceU line; 293 human Homo sapiens kidney ceU line, and CV1 African green monkey kidney ceU line were used in these experiments. CeUs were maintained in their respective media and were subcultured when they reached 60% confluency. Standard methods for culture and maintenance of the ceUs were followed.
Transfections: Several commercially available lipofactors as well as electroporation methods were evaluated and the best conditions for transfection of each cell line were developed. CHO, NIH3T3, 293 and CV1 cells were grown to 60% confluency. DNAs conesponding to the various switch constructs outlined in Examples 1.1 through 1.10 were transfected into CHO ceUs, NIH3T3 ceUs, 293 cells, or CV1 cells as foUows.
CHO ceUs: Cells were harvested when they reach 60-80% confluency and plated in 6- or 12- or 24- weU plates at 250,000, 100,000, or 50,000 ceUs in 2.5, 1.0, or 0.5 ml of growth medium containing 10% Fetal bovine serum respectively. The next day, the cells were rinsed with
growth medium and transfected for four hours. LipofectAMINE™ 2000 (Life Technologies Inc,) was found to be the best transfection reagent for these cells. For 12- well plates, 4 μl of LipofectAMINE™ 2000 was mixed with 100 μl of growth medium. 1.0 μg of reporter construct and 0.25 μg of receptor construct(s) were added to the transfection mix. A second 5 reporter construct was added [pTKRL (Promega), 0.1 μg/transfection mix] and comprised a Renilla luciferase gene (SEQ ID NO: 64) operably linked and placed under the control of a thymidine kinase (TK) constitutive promoter and was used for normalization. The contents of the transfection mix were mixed in a vortex mixer and let stand at room temperature for 30 min. At the end of incubation, the transfection mix was added to the cells maintained in 400 μl
10 growth medium. The cells were maintained at 37°C and 5% C02 for four hours. At the end of incubation, 500 μl of growth medium containing 20% FBS and either DMSO (control) or a DMSO solution of appropriate Ugands were added and the ceUs were maintained at 37 °C and 5% CO2 for 24-48 hr. The cells were harvested and reporter activity was assayed. The same procedure was followed for 6 and 24 weU plates as weU except aU the reagents were doubled
15 for 6 well plates and reduced to half for 24- well plates.
NIH3T3 CeUs: Superfect™ (Qiagen Inc.) was found to be the best transfection reagent for 3T3 ceUs. The same procedures described for CHO cells were foUowed for 3T3 ceUs as well with two modifications. The ceUs were plated when they reached 50% confluency. 125,000 or 50,000 or 25,000 ceUs were plated per well of 6- or 12- or 24-weU plates respectively. The
20 GA14EcR/VP16RXR and reporter vector DNAs were transfected into NIH3T3 cells, the transfected cells were grown in medium containing PonA, MurA, N-(2-ethyl-3- methoxybenzoyl)-N'-(3,5-dimethylbenzoyl)-N'-t-butylhydrazine, or N-(3,4-(l ,2- ethylenedioxy)-2-methylbenzoyl)-N'-(3,5-dimethylbenzoyl)-N'-tert-butylhydrazine for 48 hr. The Ugand treatments were performed as described in the CHO cell section above.
25 293 Cells: LipofectAMINE™ 2000 (Life Technologies) was found to be the best lipofactor for
293 ceUs. The same procedures described for CHO were foUowed for 293 ceUs except that the cells were plated inbiocoated plates to avoid clumping. The Ugand treatments were performed as described in the CHO cell section above. CVl CeUs: LipofectAMINE™ plus (Life Technologies) was found to be the best lipofactor
30 for CVl cells. The same procedures described for NIH3T3 ceUs were followeS for CVl ceUs
Ligands: Ponasterone A and Muristerone A were purchased from Sigma Chemical Company. The two non-steroids N-(2-ethyl-3-methoxybenzoyl)-N'-(3,5-dimethylbenzoyl)-N'-t-
butylhydrazine, or N-(3,4-(l ,2-ethylenedioxy)-2-methylbenzoyl)-N'-(3 ,5-dimethylbe__zoyl)-N'- tert-butylhydrazine are synthetic stable ecdysteroids synthesized at Rohm and Haas Company. All Ugands were dissolved in DMSO and the final concentration of DMSO was maintained at 0.1% in both controls and treatments.
Reporter Assays: CeUs were harvested 24-48 hr after adding Ugands. 125, 250, or 500 μl of passive lysis buffer (part of Dual-luciferase™ reporter assay system from Promega Corporation) were added to each well of 24- or 12- or 24-well plates respectively. The plates were placed on a rotary shaker for 15 min. Twenty μl of lysate was assayed. Luciferase activity was measured using Dual-luciferase™ reporter assay system from Promega
Corporation foUowing the manufacturer's instructions. β-Galactosidase was measured using Galacto-Star™ assay kit from TROPIX following the manufacturer' s instructions. All luciferase and β-galactosidase activities were normaUzed using Renilla luciferase as a standard. Fold activities were calculated by dividing normalized relative Ught units ("RLU") in ligand treated cells with normalized RLU in DMSO treated cells (untreated control). The results of these experiments are provided in the following tables.
Table 1 Transactivation of reporter genes through various switches in CHO cells
Table 2 Transactivation of reporter genes through various switches in 3T3 cells
Table 3 Transactivation of reporter genes through various switches in 293 cells
Table 4 Transactivation of reporter genes through various switches in CVl cells
Table 5
Transactivation of reporter gene GAL4CfEcRDEF/VP16MmRXRDEF (switch 1.1) through steroids and non-steroids in 3T3 cells.
Table 6
Transactivation of reporter gene GAL4MmRXRDEF/VP16CfEcRCDEF (switch 1.3) through steroids and non-steroids in 3T3 cells.
Applicants' results demonstrate that the non-steroidal ecdysone agonists, N-(2-ethyl-3- methoxybe__zoyl)-N' -(3,5-dimethylbenzoyl)-N' -tert-butylhydrazine and N' -(3 ,4-( 1 ,2- ethylenedioxy)-2-methylbenzoyl)-N' -(3 ,5-dimethylbenzoyl)-N' -tert-butylhydrazine, were more potent activators of CfEcR as compared to Drosophila melanogaster EcR (DmEcR). (see Tables 1-4). Also, in the mammaUan ceU Unes tested, MmRXR performed better than CfUSP as a heterodimeric partner for CfEcR. (see Tables 1-4). AdditionaUy, Applicants' inducible gene expression modulation system performed better when exogenous MmRXR was used than when the system reUed only on endogenous RXR levels (see Tables 1-4).
Applicants' results also show that in a CfEcR-based inducible gene expression system, the non-steroidal ecdysone agonists induced reporter gene expression at a lower concentration (i.e., increased ligand sensitivity) as compared to the steroid Ugands, ponasterone A and muristerone A (see Tables 5 and 6).
Out of 10 EcR based gene switches tested, the GAL4EcR/VP16RXR switch (Switch 1.1) performed better than any other switch in aU four ceU Unes examined and was more sensitive to non-steroids than steroids. The results also demonstrate that placing the activation domain (AD) and DNA binding domain (DNABD) on each of the two partners reduced background when compared to placing both AD and DNABD together on one of the two partners. Therefore, a switch format where the AD and DNABD are separated between two partners, works well for EcR-based gene switch appUcations. In addition, the MmRXR/EcR-based switches performed better than CfUSP/EcR- based switches, which have a higher background activity than the MmRXR/EoR switches in the absence of Ugand.
FinaUy, the GAL4EcR/VP16RXR switch (Switch 1.1) was more sensitive to non- steroid Ugands than to the steroid Ugands (see Tables 5 and 6). In particular, steroid Ugands
initiated transactivation at concentrations of 50 μM, whereas the non-steroid Ugands initiated transactivation at less than 1 μM (submicromolar) concentration.
EXAMPLE 2
This Example describes Applicants' further analysis of truncated EcR and RXR polypeptides in the improved EcR-based inducible gene expression system of the invention. To identify the best combination and length of two receptors that give a switch with a) maximum induction in the presence of ligand; b) minimum background in the absence of Ugand; c) highly sensitive to Ugand concentration; and d) minimum cross-talk among Ugands and receptors, AppUcants made and analyzed several truncation mutations of the CfEcR and MmRXR receptor polypeptides in NIH3T3 ceUs.
Briefly, polynucleotides encoding EcR or RXR receptors were trancated at the junctions of A/B, C, D, E and F domains and fused to either a GAL4 DNA binding domain encoding polynucleotide (SEQ ID NO: 41) for CfEcR, or a VP16 activation domain encoding polynucleotide (SEQ ID NO: 45) for MmRXR as described in Example 1. The resulting receptor truncation/fusion polypeptides were assayed in NIH3T3 ceUs. Plasmid pFRLUC (Stratagene) encoding a luciferase polypeptide was used as a reporter gene construct and pTKRL (Promega) encoding a Renilla luciferase polypeptide under the control of the constitutive TK promoter was used to normaUze the transfections as described above. The analysis was performed in triplicates and mean luciferase counts were determined as described above. Gene Expression Cassettes Encoding Truncated Ecdysone Receptor Polypeptides
Gene expression cassettes comprising polynucleotides encoding either full length or truncated CfEcR polypeptides fused to a GAL4 DNA binding domain (SEQ ID NO: 41):
GAL4CfEcRA/BCDEF (full length CfEcRA/BCDEF; SEQ ID NO: 49), GAL4CfEcRCDEF (CfEcRCDEF; SEQ ID NO: 1), GAL4CfEcRl/2CDEF (CfEcRl/2CDEF; SEQ ID NO: 2), GAL4CfEcRDEF (CfEcRDEF; SEQ ID NO: 3), GAL4CfEcREF (CfEcREF; SEQ ID NO: 4), and GAL4CfEcRDE (CfEcRDE; SEQ ID NO: 5) were transfected into NIH3T3 ceUs along with VP16MmRXRDEF (constructed as in Example 1.1; Figure 11) or VPlόj imRXREF
[constracted as in Example 1.1 except that MmRXRDEF was replaced with MmRXREF (SEQ ID NO: 23); Figure 12], and pFRLUc and pTKRL plasmid DNAs. The transfected ceUs were grown in the presence 0, 1, 5 or 25 uM of N-(2-ethyl-3-methoxybenzoyl)-N'-(3,5-
dimethylbenzoyl)-N' -tert-butylhydrazine or PonA for 48 hr. The cells were harvested, lysed and luciferase reporter activity was measured in the cell lysates. Total fly luciferase relative light units are presented. The number on the top of each bar is the maximum fold induction for that treatment. AppUcants' results show that the EF domain of MmRXR is sufficient and performs better than DEF domains of this receptor (see Figures 11 and 12). Applicants have also shown that, in general, EcR/RXR receptor combinations are insensitive to PonA (see Figures 11 and 12). As shown in the Figures 11 and 12, the GAL4CfEcRCDEF hybrid polypeptide (SEQ ID NO: 7) performed better than any other CfEcR hybrid polypeptide. Gene Expression Cassettes Encoding Trancated Retinoid X Receptor Polypeptides
Gene expression cassettes comprising polynucleotides encoding either full length or truncated MmRXR polypeptides fused to a VP16 transactivation domain (SEQ ID NO: 45): VP16MmRXRA/BCDEF (full length MmRXRA/BCDEF; SEQ ID NO: 53), VP16MmRXRCDEF (MmRXRCDEF; SEQ ID NO: 21), VP16MmRXRDEF (MmRXRDEF; SEQ ID NO: 22), VP16MmRXREF (MmRXREF; SEQ ID NO: 23),
VP16MmRXRBam-EF ("MmRXRBam-EF" or "MmRXR-trancatedEF"; SEQ ID NO: 24), and VP16MmRXRAF2del ("MmRXRAF2del" or "MmRXR-E"; SEQ ID NO: 25) constracts were transfected into NIH3T3 cells along with GAL4CfEcRCDEF (constracted as in Example 1.1; Figure 13) or GAL4CfEcRDEF [constracted as in Example 1.1 except CfEcRCDEF was replaced with CfEcRDEF (SEQ ID NO: 3); Figure 14], pFRLUc and pTKRL plasmid DNAs as described above. The transfected ceUs were grown in the presence 0, 1, 5 and 25 uM of N- (2-ethyl-3-methoxybenzoyl)-N'-(3,5-dimethylbenzoyl)-N'-tert-butylhydrazine or PonA for 48 hr. The ceUs were harvested and lysed and reporter activity was measured in the cell lysate. Total fly luciferase relative light units are presented. The number on top of each bar is the maximum fold induction in that treatment.
Of all the truncations of MmRXR tested, AppUcants' results show that the MmRXREF receptor was the best partner for CfEcR (Figures 13 and 14). CfEcRCDEF showed better induction than CfEcRDEF using MmRXREF. Deleting AF2 (abbreviated "EF- AF2del") or helices 1-3 of the E domain (abbreviated "EF-Bamdel") resulted in an RXR receptor that reduced gene induction and Ugand sensitivity when partnered wittø. either
CfEcRCDEF (Figure 13) or CfEcRDEF (Figure 14) in NIH3T3 cells. In general, the CfEcR/RXR-based switch was much more sensitive to the non-steroid N-(2-ethyl-3- methoxybenzoyl)-N' -(3 ,5-dimethylbenzoyl)-N' -tert-butylhydrazine than to the steroid PonA.
EXAMPLE 3
This Example describes AppUcants' further analysis of gene expression cassettes encoding truncated EcR or RXR receptor polypeptides that affect either ligand binding activity or ligand sensitivity, or both. Briefly, six different combinations of chimeric receptor pairs, constructed as described in Examples 1 and 2, were further analyzed in a single experiment in NIH3T3 ceUs. These six receptor pair combinations and their conesponding sample numbers are depicted in Table 7.
Table 7 CfEcR + MmRXR Truncation Receptor Combinations in NIH3T3 Cells
The above receptor construct pairs, along with the reporter plasmid pFRLuc were transfected into NIH3T3 cells as described above. The six CfEcR trancation receptor combinations were duplicated into two groups and treated with either steroid (odd numbers on x-axis of Figure 15) or non-steroid (even numbers on x-axis of Figure 15). In particular, the ceUs were grown in media containing 0, 1, 5 or 25 uM PonA (steroid) or N-(2-ethyl-3- methoxybenzoyl)-N'-(3,5-dimethylbenzoyl)-N'-tert-butylhydrazine (non-steroid) ligand. The reporter gene activity was measured and total RLU are shown. The number on top of each bar is the maximum fold induction for that treatment and is the mean of three repUcates.
As shown in Figure 15, the CfEcRCDEF/MmRXREF receptor combinations were the best switch pairs both in terms of total RLU and fold induction (compare columns 1-6 to columns 7-12). This confirms Applicants' earUer findings as described in Example 2 (Figures 11-14). The same gene expression cassettes encoding the truncated EcR and RXR polypeptides were also assayed in a human lung carcinoma ceU Une A549 (ATCC) and similar results were observed (data not shown).
Claims (71)
1. A gene expression modulation system comprising : a) a first gene expression cassette that is capable of being expressed in a host cell comprising a polynucleotide sequence that encodes a first polypeptide comprising: i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; i) a Ugand binding domain comprising a Ugand binding domain from a nuclear receptor; b) a second gene expression cassette that is capable of being expressed in the host ceU comprising a polynucleotide sequence that encodes a second polypeptide comprising: i) a transactivation domain; and n) a ligand binding domain comprising a Ugand binding domain from a nuclear receptor other than ultraspiracle (USP) ; wherein the transactivation domain is from a nuclear receptor other than an ecdysone receptor, a retinoid X receptor, or an ultraspiracle receptor; and wherein the Ugand binding domains from the first polypeptide and the second polypeptide are different and dimerize.
2. The gene expression modulation system according to claim 1 , further comprising a third gene expression cassette comprising: i) a response element to which the DNA-binding domain of the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and iii) the gene whose expression is to be modulated.
3. The gene expression modulation system according to claim 1 , wherein the ligand binding domain of the first polypeptide is an ecdysone receptor polypeptide.
4. The gene expression modulation system according to claim 1 , wherein the ligand binding domain of the second polypeptide is a retinoid X receptor polypeptide.
5. A gene expression modulation system comprising: a) a first gene expression cassette that is capable of being expressed in a host cell comprising a polynucleotide sequence that encodes a first polypeptide comprising: i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and U) a ligand binding domain comprising a Ugand binding domain from an ecdysone receptor; and b) a second gene expression cassette that is capable of being expressed in the host ceU comprising a polynucleotide sequence that encodes a second polypeptide comprising: i) a transactivation domain; and n) a ligand binding domain comprising a Ugand binding domain from a retinoid X receptor; wherein the Ugand binding domains from the first polypeptide and the second polypeptide are different and dimerize.
6. The gene expression modulation system according to claim 5, further comprising a third gene expression cassette comprising: i) a response element to which the DNA-binding domain of the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and in) the gene whose expression is to be modulated.
7. The gene expression modulation system according to claim 5, wherein the ligand binding domain of the first polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
8. The gene expression modulation system according to claim 5, wherein the ligand binding domain of the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14,
SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
9. The gene expression modulation system according to claim 5, wherein the Ugand binding domain of the second polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SJ3Q ID NO: 22,
SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
10. The gene expression modulation system according to claim 5, wherein the ligand binding domain of the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
11. A gene expression modulation system comprising: a) a first gene expression cassette that is capable of being expressed in a host cell comprising a polynucleotide sequence that encodes a first polypeptide comprising: i) a DNA-binding domain that recognizes a response element associated with a gene whose expression is to be modulated; and U) a ligand binding domain comprising a Ugand binding domain from a retinoid X receptor; and b) a second gene expression cassette that is capable of being expressed in the host ceU comprising a polynucleotide sequence that encodes a second polypeptide comprising: i) a transactivation domain; and n) a ligand binding domain comprising a Ugand bmding domain from an ecdysone receptor; wherein the Ugand binding domains from the first polypeptide and the second polypeptide are different and dimerize.
12. The gene expression modulation system according to claim 11 , further comprising a third gene expression cassette comprising: i) a response element to which the DNA-binding domain of the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and ϋi) the gene whose expression is to be modulated.
13. The gene expression modulation system according to claim 11 , wherein the ligand binding domain of the first polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ EQ,NO: 27, SEQ
ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
14. The gene expression modulation system according to claim 11 , wherein the ligand binding domain of the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
15. The gene expression modulation system according to claim 11 , wherein the ligand binding domain of the second polypeptide is encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
16. The gene expression modulation system according to claim 11 , wherein the ligand binding domain of the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
17. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a DNA-binding domain and an ecdysone receptor Ugand binding domain, wherein the DNA binding domain is from a nuclear receptor other than an ecdysone receptor.
18. The gene expression cassette according to claim 18, wherein the DNA-binding domain is a GAL4 DNA-binding domain or a LexA DNA-binding domain.
19. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a DNA-binding domain and a retinoid X receptor ligand binding domain, wherein the DNA binding domain is from a nuclear receptor other than a retinoid X receptor.
20. The gene expression cassette according to claim 19, wherein the DNA-binding domain is a GAL4 DNA-binding domain or a LexA DNA-binding domain.
21. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a transactivation domain and an ecdysone receptor Ugand binding domain, wherein the transactivation domain is from a nuclear receptor other than an ecdysone receptor.
22. The gene expression cassette according to claim 21, wherein the transactivation domain is a VP16 transactivation domain.
23. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a transactivation domain and a retinoid X receptor ligand binding domain, wherein the transactivation domain is from a nuclear receptor other than a retinoid X receptor.
24. The gene expression cassette according to claim 22, wherein the transactivation domain is a VP16 transactivation domain. 5
25. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a DNA-binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 41) or a LexA DBD (SEQ ID NO: 43) and an ecdysone receptor Ugand binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ 10 ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
26. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a DNA-binding domain comprising an amino acid sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 42) or a LexA DBD (SEQ ID NO:
15 44) and an ecdysone receptor Ugand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
27. A gene expression cassette comprising a polynucleotide encoding a hybrid 20 polypeptide comprising a DNA-binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 41) or a LexA DBD (SEQ ID NO: 43) and a retinoid X receptor ligand binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID
25 NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
28. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a DNA-binding domain comprising an amino acid sequence selected from the group consisting of a GAL4 DBD (SEQ ID NO: 42) or a LexA DBD (SEQ ID NO: 44) and a retinoid X receptor Ugand binding domain comprising an amino acid sequence
30 selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ.ID NO: 33, SEQ
ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
29. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a transactivation domain encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO: 45 and an ecdysone receptor ligand binding domain encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, 5 SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
30. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a transactivation domain comprising an amino acid sequence of SEQ ID NO: 46 and an ecdysone receptor Ugand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO:
10 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
31. A gene expression cassette comprising a polynucleotide encoding a hybrid polypeptide comprising a transactivation domain encoded by a polynucleotide comprising a nucleic acid sequence of SEQ ID NO: 45 and a retinoid X receptor ligand binding domain
15 encoded by a polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
32. A gene expression cassette comprising a polynucleotide encoding a hybrid
20 polypeptide comprising a transactivation domain comprising an amino acid sequence of SEQ ID NO: 46 and a retinoid X receptor Ugand binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
25 33. An isolated polynucleotide encoding an ecdysone receptor polypeptide or a retinoid X receptor polypeptide comprising a truncation mutation, wherein the trancation mutation reduces Ugand binding activity of the ecdysone receptor polypeptide or the retinoid X receptor polypeptide.
34. An isolated polynucleotide encoding an ecdysone receptor polypeptide or a
30 retinoid X receptor polypeptide comprising a truncation mutation, wherein the rancation mutation reduces steroid binding activity of the ecdysone receptor polypeptide or the retinoid X receptor polypeptide.
35. An isolated polynucleotide encoding an ecdysone receptor polypeptide or a retinoid X receptor polypeptide comprising a truncation mutation, wherein the trancation mutation reduces non-steroid binding activity of the ecdysone receptor polypeptide or the retinoid X receptor polypeptide.
36. An isolated polynucleotide encoding an ecdysone receptor polypeptide or a retinoid X receptor polypeptide comprising a truncation mutation, wherein the truncation mutation enhances Ugand binding activity of the ecdysone receptor polypeptide or the retinoid X receptor polypeptide.
37. An isolated polynucleotide encoding an ecdysone receptor polypeptide or a retiαoid X receptor polypeptide comprising a truncation mutation, wherein the truncation mutation enhances steroid binding activity of the ecdysone receptor polypeptide or the retinoid X receptor polypeptide.
38. An isolated polynucleotide encoding an ecdysone receptor polypeptide or a retinoid X receptor polypeptide comprising a trancation mutation, wherein the truncation mutation enhances non-steroid binding activity of the ecdysone receptor polypeptide or the retinoid X receptor polypeptide.
39. An isolated polynucleotide encoding a retinoid X receptor polypeptide comprising a truncation mutation, wherein the truncation mutation increases Ugand sensitivity of the retinoid X receptor polypeptide.
40. An isolated polynucleotide encoding a retinoid X receptor polypeptide comprising a trancation mutation, wherein the truncation mutation increases Ugand sensitivity of a heterodimer, wherein the heterodimer comprises said retinoid X receptor polypeptide and a dimerization partner.
41. The isolated polynucleotide according to clai 40, wherein the dimerization partner is an ecdysone receptor polypeptide.
42. An isolated polynucleotide encoding a truncated ecdysone receptor polypeptide, wherein the polynucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.
43. An isolated polypeptide encoded by the isolated polynucleotide according to claim 42.
44. An isolated truncated ecdysone receptor polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
45. An isolated polynucleotide encoding a truncated retinoid X receptor polypeptide, wherein the polynucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30.
46. An isolated polypeptide encoded by the isolated polynucleotide according to claim 45.
47. An isolated truncated retinoid X receptor polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 31 , SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40.
48. A method of modulating the expression of a gene in a host cell comprising the gene to be modulated comprising the steps of: a) introducing into the host ceU the gene expression modulation system according to claim 1; and b) introducing into the host ceU a ligand that independently combines with the ligand binding domains of the first polypeptide and the second polypeptide; wherein the gene to be expressed is a component of a chimeric gene comprising: i) a response element to which the DNA binding domain from the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and iii) a gene whose expression is to be modulated, whereby a complex is formed comprising the Ugand, the first polypeptide, and the second polypeptide, and whereby the complex modulates expression of the gene in the host cell.
49. The method according to claim 48, wherein the ligand is a compound of the formula: wherein:
E is a (C4-C6)alkyl containing a tertiary carbon or a cyano(C3-C5)alkyl containing a tertiary carbon; R1 is H, Me, Et, i-Pr, F, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-proρynyl, 2-propynyl, vinyl, OH, OMe, OEt, cyclopropyl, CF2CF3, CH=CHCN, allyl, azido, SCN, or SCHF2; R2 is H, Me, Et, n-Pr, i-Pr, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, Ac, F, CI, OH, OMe, OEt, O-n- Pr, OAc, NMez, NEt2, SMe, SEt, SOCF3, OCF2CF2H, COEt, cyclopropyl, CF2CF3,
CH=CHCN, allyl, azido, OCF3, OCHF2, O-i-Pr, SCN, SCHF2, SOMe, NH-CN, or joined with R3 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon; R3 is H, Et, or joined with R2 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon; R4, R5, and R6 are independently H, Me, Et, F, CI, Br, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or SEt.
50. A method of modulating the expression of a gene in a host cell comprising the gene to be modulated comprising the steps of: a) introducing into the host cell the gene expression modulation system of claim 5; and b) introducing into the host ceU a ligand that independently combines with the ligand binding domains of the first polypeptide and the second polypeptide; wherein the gene to be expressed is a component of a chimeric gene comprising: i) a response element to which the DNA binding domain from the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and in) a gene whose expression is to be modulated, whereby a complex is formed comprising the Ugand, the first polypeptide, and the second polypeptide, and whereby the.complex modulates expression of the gene in the host cell.
51. The method according to claim 50, wherein the ligand is a compound of the formula:
wherein: E is a (C4-C6)alkyl containing a tertiary carbon or a cyano(C3-Cs)alkyl containing a tertiary carbon; R1 is H, Me, Et, i-Pr, F, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-proρynyl, 2-propynyl, vinyl, OH, OMe, OEt, cyclopropyl, CF2CF3, CH=CHCN, allyl, azido, SCN, or SCHF2; R2 is H, Me, Et, n-Pr, i-Pr, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-proρynyl, 2-propynyl, vinyl, Ac, F, CI, OH, OMe, OEt, O-n- Pr, OAc, NMej, NEt2, SMe, SEt, SOCF3, OCF2CF2H, COEt, cyclopropyl, CF2CF3, CH=CHCN, allyl, azido, OCF3, OCHF2, O-i-Pr, SCN, SCHF2, SOMe, NH-CN, or joined with R3 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon; R3 is H, Et, or joined with R2 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon; R4, R5, and R6 are independently H, Me, Et, F, CI, Br, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or SEt.
52. A method of modulating the expression of a gene in a host cell comprising the gene to be modulated comprising the steps of: a) introducing into the host cell the gene expression modulation system of claim 11; and b) introducing into the host ceU a ligand that independently combines with the ligand binding domains of the first polypeptide and the second polypeptide; wherein the gene to be expressed is a component of a chimeric gene comprising: i) a response element to which the DNA binding domain from the first polypeptide binds; ii) a promoter that is activated by the transactivation domain of the second polypeptide; and iu) a gene whose expression is to be modulated, whereby a complex is formed comprising the Ugand, the first polypeptide, and the second polypeptide, and whereby the complex modulates expression of the gene in the host cell.
53. The method according to claim 52, wherein the ligand is a compound of the formula:
wherein:
E is a (C4-C6)alkyl containing a tertiary carbon or a cyano(C3-C5)alkyl containing a tertiary carbon; R1 is H, Me, Et, i-Pr, F, formyl, CF3, CHF2, CHC12> CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, OH, OMe, OEt, cyclopropyl,
CF2CF3, CH=CHCN, allyl, azido, SCN, or SCHF2; R2 is H, Me, Et, n-Pr, i-Pr, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CH2OMe, CH2CN, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, Ac, F, CI, OH, OMe, OEt, O-n- Pr, OAc, NMe^, NEt2, SMe, SEt, SOCF3, OCF2CF2H, COEt, cyclopropyl, CF2CF3, CH=CHCN, allyl, azido, OCF3, OCHF2, O-i-Pr, SCN, SCHF2, SOMe, NH-CN, or joined with R3 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon; R3 is H, Et, or joined with R2 and the phenyl carbons to which R2 and R3 are attached to form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a phenyl carbon; R4, R5, and R6 are independently H, Me, Et, F, CI, Br, formyl, CF3, CHF2, CHC12, CH2F, CH2C1, CH2OH, CN, C°CH, 1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or SEt.
54. An isolated host ceU into which the gene expression modulation system according to claim 1 has been introduced.
55. The isolated host ceU according to claim 54, wherein the host cell is selected from the group consisting of a bacterial cell, a fungal ceU, a yeast cell, a plant cell, an animal cell, and a mammaUan cell.
56. The isolated host cell according to claim 55, wherein the host cell is a plant ceU, a murine ceU, or a human cell.
57. An isolated host ceU into which the gene expression modulation system according to claim 5 has been introduced.
58. The isolated host ceU according to claim 57, wherein the host cell is selected from the group consisting of a bacterial cell, a fungal ceU, a yeast cell, a plant cell, an animal cell, and a mammaUan cell.
59. The isolated host ceU according to claim 58, wherein the host cell is a plant ceU, a murine ceU, or a human cell.
60. An isolated host ceU into which the gene expression modulation system according to claim 11 has been introduced.
61. The isolated host ceU according to claim 60, wherein the host cell is selected from the group consisting of a bacterial ceU, a fungal ceU, a yeast cell, a plant cell, an animal cell, and a mammaUan ceU.
62. The isolated host cell according to claim 61 , wherein the host cell is a plant ceU, a murine ceU, or a human cell.
63. A non-human organism comprising a host cell into which the gene expression modulation system according to claim 1 has been introduced.
64. The non-human organism according to claim 63 , wherein the aon-human organism is selected from the group consisting of a bacterium, a fungus, a yeast, a plant, an animal, and a mammal.
65. The non-human organism according to claim 64, wherein the non-human organism is selected from the group consisting of a plant, a mouse, a rat, a rabbit, a cat, a dog, a bovine, a goat, a pig, a horse, a sheep, a monkey, and a chimpanzee.
66. A non-human organism comprising a host cell into which the gene expression modulation system according to claim 5 has been introduced.
67. The non-human organism according to claim 66, wherein the non-human organism is selected from the group consisting of a bacterium, a fungus, a yeast, a plant, an animal, and a mammal.
68. The non-human organism according to claim 67, wherein the non-human organism is selected from the group consisting of a plant, a mouse, a rat, a rabbit, a cat, a dog, a bovine, a goat, a pig, a horse, a sheep, a monkey, and a chimpanzee.
69. A non-human organism comprising a host ceU into which the gene expression modulation system according to claim 11 has been introduced.
70. The non-human organism according to claim 69, wherein the non-human organism is selected from the group consisting of a bacterium, a fungus, a yeast, a plant, an animal, and a mammal.
71. The non-human organism according to claim 70, wherein the non-human organism is selected from the group consisting of a plant, a mouse, a rat, a rabbit, a cat, a dog, a bovine, a goat, a pig, a horse, a sheep, a monkey, and a chimpanzee.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007200882A AU2007200882B2 (en) | 2000-03-22 | 2007-02-28 | Ecdysone receptor-based inducible gene expression system |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19135500P | 2000-03-22 | 2000-03-22 | |
US60/191,355 | 2000-03-22 | ||
US26979901P | 2001-02-20 | 2001-02-20 | |
US60/269,799 | 2001-02-20 | ||
PCT/US2001/009050 WO2001070816A2 (en) | 2000-03-22 | 2001-03-21 | Ecdysone receptor-based inducible gene expression system |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001249315A1 true AU2001249315A1 (en) | 2001-10-03 |
Family
ID=26886975
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001249315A Abandoned AU2001249315A1 (en) | 2000-03-22 | 2001-03-21 | Ecdysone receptor-based inducible gene expression system |
AU2007200882A Ceased AU2007200882B2 (en) | 2000-03-22 | 2007-02-28 | Ecdysone receptor-based inducible gene expression system |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007200882A Ceased AU2007200882B2 (en) | 2000-03-22 | 2007-02-28 | Ecdysone receptor-based inducible gene expression system |
Country Status (11)
Country | Link |
---|---|
US (1) | US7091038B2 (en) |
EP (1) | EP1266015B1 (en) |
JP (1) | JP5031967B2 (en) |
CN (1) | CN1304578C (en) |
AR (1) | AR028276A1 (en) |
AT (1) | ATE338135T1 (en) |
AU (2) | AU2001249315A1 (en) |
CA (1) | CA2404253C (en) |
DE (1) | DE60122685T2 (en) |
MX (1) | MXPA02009157A (en) |
WO (1) | WO2001070816A2 (en) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
US8105825B2 (en) * | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
WO2002061102A2 (en) * | 2000-10-24 | 2002-08-08 | Syngenta Participations Ag | Control of gene expression in plants |
JP4328094B2 (en) | 2001-02-20 | 2009-09-09 | イントレクソン・コーポレイション | Novel substitution mutant receptors and their use in nuclear receptor-based inducible gene expression systems |
DK1534738T3 (en) | 2001-02-20 | 2012-10-01 | Intrexon Corp | Novel substitution mutant receptors and their use in an inducible gene expression system based on a nuclear receptor |
AU2002247184B2 (en) | 2001-02-20 | 2008-06-19 | Intrexon Corporation | Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system |
JP4955905B2 (en) * | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | Chimeric retinoid X receptors and their use in novel ecdysone receptor-based inducible gene expression systems |
DE10244149A1 (en) * | 2001-09-25 | 2003-04-30 | Werner Keber | Preventing prohibited approaches by aircraft to ground objects to be protected involves virtual prohibited zones providing adequate horizontal separation, minimum vertical separation |
CA2459807C (en) | 2001-09-26 | 2013-09-03 | Jianzhong Zhang | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
CA2820144C (en) | 2001-09-26 | 2017-06-20 | Intrexon Corporation | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
US7744862B2 (en) * | 2002-02-05 | 2010-06-29 | Geymonat S.P.A. | Production process of recombinant placental growth factor |
US9154906B2 (en) | 2002-03-28 | 2015-10-06 | Telecommunication Systems, Inc. | Area watcher for wireless network |
US7375093B2 (en) * | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
JP4634931B2 (en) * | 2003-02-07 | 2011-02-16 | クミアイ化学工業株式会社 | Molting hormone receptor and screening method for ligand for the receptor |
US7304161B2 (en) * | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
AU2011202682B2 (en) * | 2003-02-10 | 2013-11-28 | Intrexon Corporation | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7790377B2 (en) | 2003-08-29 | 2010-09-07 | The University Of North Carolina At Greensboro | Compounds that act to modulate insect growth and methods and systems for identifying such compounds |
US8637237B2 (en) | 2003-08-29 | 2014-01-28 | The University Of North Carolina At Greensboro | Methods, compositions, and systems for the identification of species-specific or developmental stage-specific insecticides |
US20050164210A1 (en) * | 2004-01-23 | 2005-07-28 | Vivek Mittal | Regulated polymerase III expression systems and related methods |
US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
JP4517347B2 (en) * | 2004-07-02 | 2010-08-04 | 国立大学法人北海道大学 | Method for detecting estrogenic substances using plants |
US8097431B2 (en) * | 2004-08-04 | 2012-01-17 | University Of Utah Research Foundation | Methods and compositions for detecting steroids |
US8115059B1 (en) | 2005-07-22 | 2012-02-14 | University Of Kentucky Research Foundation | Gene expression modulation system for use in plants and method for modulating gene expression in plants |
AU2006272922A1 (en) | 2005-07-22 | 2007-02-01 | Amgen Inc. | Aniline sulfonamide derivatives and their uses |
WO2008073154A2 (en) | 2006-07-26 | 2008-06-19 | Intrexon Corporation | Methods and compositions for treating disease |
CN101016518B (en) * | 2006-09-12 | 2010-07-28 | 南方医科大学 | Biological insecticide screening model and its preparing method and application |
EP2557091A1 (en) | 2007-05-02 | 2013-02-13 | Intrexon Corporation | PP1 ligands |
CN104761466A (en) | 2007-05-29 | 2015-07-08 | 英特拉克森公司 | Chiral diacylhydrazine ligands for modulating expression of exogenous genes via ecdysone receptor complex |
CN101835908A (en) | 2007-08-23 | 2010-09-15 | 英特瑞克斯顿股份有限公司 | The method and composition that diagnoses the illness |
NZ583992A (en) * | 2007-09-17 | 2012-11-30 | Rohm & Haas | A gene expression system for controllable expression of ethylene response in a plant |
MX2010003371A (en) | 2007-09-28 | 2010-05-05 | Intrexon Corp | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof. |
CA2702058A1 (en) * | 2007-10-08 | 2009-04-16 | Intrexon Corporation | Engineered dendritic cells and uses for the treatment of cancer |
JP5777890B2 (en) * | 2008-03-14 | 2015-09-09 | イントレキソン コーポレーション | Steroid ligands and their use in gene switch modulation |
AU2009302804B2 (en) | 2008-10-08 | 2015-07-02 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
CN102361976A (en) | 2009-03-05 | 2012-02-22 | 罗门哈斯公司 | Control of targeted turnover of key ethylene hormone signaling pathway proteins to modulate ethylene sensitivity in plants |
TWI688395B (en) | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
JP5719443B2 (en) | 2010-09-26 | 2015-05-20 | ダ・ユー・エンタープライジズ、エルエルシー | Recombinant macromolecule production method |
WO2012122025A2 (en) | 2011-03-04 | 2012-09-13 | Intrexon Corporation | Vectors conditionally expressing protein |
EP3699286A1 (en) | 2011-04-20 | 2020-08-26 | The Trustees of the University of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
CN105283439B (en) | 2013-03-15 | 2018-02-02 | 英特瑞克斯顿股份有限公司 | The dibenzoylhydrazine of boracic |
WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
US11053513B2 (en) | 2013-07-15 | 2021-07-06 | Donald Danforth Plant Science Center | Enhanced oil production and stress tolerance in plants |
CN103555727B (en) * | 2013-10-14 | 2015-06-10 | 中国水产科学研究院淡水渔业研究中心 | Living molecular detection method for precocious puberty individual of Eriocheir sinensis |
US9944659B2 (en) | 2014-09-17 | 2018-04-17 | Intrexon Corporation | Boron-containing diacylhydrazine compounds |
US20180348231A1 (en) * | 2015-03-30 | 2018-12-06 | Intrexon Corporation | Ligand inducible polypeptide coupler system |
WO2016200543A2 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
US20190062394A1 (en) | 2015-10-10 | 2019-02-28 | Intrexon Corporation | Improved Therapeutic Control of Proteolytically Sensitive, Destabilized Forms of Interleukin-12 |
BR112018009645A2 (en) | 2015-11-11 | 2018-11-13 | Intrexon Corp | compositions and methods for the expression of various biologically active polypeptides from a single vector for treatment of cardiac conditions and other conditions |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Neoantigen identification, manufacture, and use |
AU2017279548A1 (en) | 2016-06-08 | 2018-12-13 | Precigen, Inc. | Cd33 specific chimeric antigen receptors |
UY37343A (en) | 2016-07-25 | 2018-02-28 | Intrexon Corp | CONTROL OF THE PHENOTYPE IN PLANTS |
BR112019009446A2 (en) | 2016-11-09 | 2019-07-30 | Intrexon Corp | frataxin expression constructs |
CN106589125B (en) * | 2016-12-23 | 2020-04-14 | 江苏省农业科学院 | Monoclonal antibody of anti-lygus lucorum ecdysone receptor protein and application thereof |
AU2018207281A1 (en) | 2017-01-10 | 2019-07-18 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
DK3589730T3 (en) | 2017-02-28 | 2024-03-04 | Univ Pennsylvania | CLADE F ADENO-ASSOCIATED VIRUS (AAV) VECTOR AND USE THEREOF |
CA3052487A1 (en) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Influenza vaccines based on aav vectors |
JOP20190200A1 (en) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | Compositions useful in treatment of spinal muscular atrophy |
KR102557834B1 (en) | 2017-06-07 | 2023-07-21 | 프레시전 인코포레이티드 | Expression of novel cell tags |
CN111465989A (en) | 2017-10-10 | 2020-07-28 | 磨石肿瘤生物技术公司 | Identification of neoantigens using hot spots |
JP2021503897A (en) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | Reduced junction epitope presentation for nascent antigens |
KR20200128703A (en) | 2018-03-06 | 2020-11-16 | 프레시전 인코포레이티드 | Hepatitis B vaccine and uses thereof |
CN108913732B (en) * | 2018-07-31 | 2022-02-08 | 华东理工大学 | Method for heterologous production of monacolin J and application |
CN109810993B (en) * | 2019-03-25 | 2022-05-31 | 临沂大学 | Locust beta-D-glucoside hydrolase gene and application thereof |
WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
CN110592095A (en) * | 2019-09-26 | 2019-12-20 | 浙江海洋大学 | Clone and expression of sepiella maindroni tretinoin X receptor gene |
CN114981439A (en) * | 2019-11-19 | 2022-08-30 | 芬兰国家技术研究中心股份公司 | Non-viral transcriptional activation domains and methods and uses related thereto |
AU2021390480A1 (en) | 2020-12-01 | 2023-06-22 | The Trustees Of The University Of Pennsylvania | Novel compositions with tissue-specific targeting motifs and compositions containing same |
TW202305124A (en) | 2021-04-23 | 2023-02-01 | 賓州大學委員會 | Novel compositions with brain-specific targeting motifs and compositions containing same |
WO2023056399A1 (en) | 2021-10-02 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Novel aav capsids and compositions containing same |
WO2023147304A1 (en) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
EP0522054A4 (en) | 1990-03-22 | 1993-02-10 | The Salk Institute For Biological Studies | Insect retinoid receptor compositions and methods |
WO1996027673A1 (en) * | 1995-03-03 | 1996-09-12 | Novartis Ag | Control of gene expression in plants by receptor mediated transactivation in the presence of a chemical ligand |
CA2200423C (en) * | 1996-03-26 | 2006-12-19 | Sietse Mosselman | Novel estrogen receptor |
EP0910652B1 (en) * | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US5919667A (en) * | 1996-06-20 | 1999-07-06 | The Salk Institute For Biological Studies | Modular assembly retroviral vectors and uses thereof |
EP0998560A1 (en) * | 1997-07-10 | 2000-05-10 | The Salk Institute For Biological Studies | Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression |
US6300488B1 (en) | 1997-07-10 | 2001-10-09 | The Salk Institute For Biological Studies | Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression |
US6117680A (en) * | 1997-08-26 | 2000-09-12 | Ariad Gene Therapeutics, Inc. | Compositions and methods for regulation of transcription |
US6333318B1 (en) * | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US6258603B1 (en) * | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
-
2001
- 2001-03-21 EP EP01922524A patent/EP1266015B1/en not_active Expired - Lifetime
- 2001-03-21 WO PCT/US2001/009050 patent/WO2001070816A2/en active IP Right Grant
- 2001-03-21 DE DE60122685T patent/DE60122685T2/en not_active Expired - Lifetime
- 2001-03-21 AU AU2001249315A patent/AU2001249315A1/en not_active Abandoned
- 2001-03-21 AT AT01922524T patent/ATE338135T1/en active
- 2001-03-21 MX MXPA02009157A patent/MXPA02009157A/en active IP Right Grant
- 2001-03-21 CN CNB018078443A patent/CN1304578C/en not_active Expired - Fee Related
- 2001-03-21 JP JP2001569016A patent/JP5031967B2/en not_active Expired - Fee Related
- 2001-03-21 CA CA2404253A patent/CA2404253C/en not_active Expired - Lifetime
- 2001-03-22 AR ARP010101339A patent/AR028276A1/en active IP Right Grant
- 2001-09-26 US US09/965,703 patent/US7091038B2/en not_active Expired - Lifetime
-
2007
- 2007-02-28 AU AU2007200882A patent/AU2007200882B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
US7091038B2 (en) | 2006-08-15 |
MXPA02009157A (en) | 2004-04-05 |
JP2003527852A (en) | 2003-09-24 |
DE60122685T2 (en) | 2007-08-23 |
CN1304578C (en) | 2007-03-14 |
EP1266015B1 (en) | 2006-08-30 |
DE60122685D1 (en) | 2006-10-12 |
WO2001070816A2 (en) | 2001-09-27 |
EP1266015A2 (en) | 2002-12-18 |
AU2007200882A1 (en) | 2007-03-22 |
JP5031967B2 (en) | 2012-09-26 |
CA2404253C (en) | 2014-05-13 |
WO2001070816A3 (en) | 2002-08-29 |
ATE338135T1 (en) | 2006-09-15 |
US20020119521A1 (en) | 2002-08-29 |
CA2404253A1 (en) | 2001-09-27 |
AR028276A1 (en) | 2003-04-30 |
AU2007200882B2 (en) | 2011-05-19 |
CN1422334A (en) | 2003-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8822754B2 (en) | Ecdysone receptor-based inducible gene expression system | |
EP1266015B1 (en) | Ecdysone receptor-based inducible gene expression system | |
EP2374891B1 (en) | Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system | |
EP1456346B1 (en) | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system | |
AU2002247214A1 (en) | Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system | |
AU2002247184A1 (en) | Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system | |
AU2011213797B2 (en) | Ecdysone receptor-based inducible gene expression system | |
AU2012200136B2 (en) | Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene expression system | |
IHRE et al. | BASED INDUCIBLE GENE EXPRESSION SYSTEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |